Genre: Legal

Medicines Regulations 1984 Order in Council Note Changes authorised by section 17C of the Acts and Regulations Publication Act 1989 have been made in this reprint. A general outline of these changes is set out in the notes at the end of this reprint, together with other explanatory material about this reprint. These regulations are administered by the Ministry of Health. Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. 2 Interpretation appropriate designation , in relation to a medicine, or an ingredient of a medicine, or a related product, or an active ingredient of a related product, has the following meaning in each of the cases specified: (a) where the medicine, related product, or ingredient is named or described in a monograph contained in the current edition of a specified publication, the term means the name or one of the synonyms used in that specified publication for that medicine, related product, or ingredient: (b) where the medicine, related product, or ingredient --  (i) is not named or described in a monograph contained in the current edition of any specified publication but was named or described in a monograph contained in an earlier edition; and (ii) is not sold under any name or description except the name or one of the synonyms used in that earlier edition for that medicine, related product, or ingredient, --  the term means the name or one of the synonyms so used in that earlier edition followed immediately by a reference to that earlier edition: (i) the international non-proprietary name of the medicine, related product, or ingredient; or (ii) if it has no international non-proprietary name, the name appearing in a list published in the United Kingdom on the recommendation of the Medicines Commission pursuant to section 100 of the Medicines Act 1968 (UK); or (iii) if the medicine, related product, or ingredient has neither an international non-proprietary name nor a name appearing in a list referred to in subparagraph (ii), its accepted scientific name or some other name descriptive of the true nature of the medicine, related product, or ingredient appropriate quantitative particulars , in relation to any active ingredients of a medicine or of a related product, --  (a) where the medicine or related product consists of or comprises tablets, capsules, or other separate portions, means the quantity (expressed by weight or volume) of each of the ingredients contained in each portion; or (b) in any other case, means the percentage of each of those ingredients contained in the medicine or related product, or the quantity of each of those ingredients contained in a stated quantity of the medicine or related product approved immunisation programme means a vaccination programme --  (a) pursuant to the National Immunisation Schedule of the Ministry of Health; or (b) approved by the Director-General or a Medical Officer of Health biochemical preparation includes --  (a) an antigen; and (b) an antitoxin; and (c) a toxin; and (d) a blood fractionation preparation; and (e) an insulin; and (f) a preparation from a mammalian gland; and (g) a serum; and (h) a vaccine; and (i) any other substance or preparation that is similar in nature to any of those specified in paragraphs (a) to (h), --  whether natural or synthetic, that is intended for diagnostic, prophylactic, or therapeutic purposes consent to distribute , in relation to any medicine or related product, means a consent to the distribution of that medicine or related product given by the Minister under section 20 of the Act; and includes a provisional consent given under section 23 of the Act described , in relation to any medicine, related product, or medical device, means represented or held out (whether in writing or otherwise) by the manufacturer, seller, or supplier of the medicine, related product, or medical device dispensary technician means a person who holds a certificate issued by the Pharmaceutical Society of New Zealand before 18 September 2004 that --  (a) classifies the holder as a dispensary assistant; or (b) records that the person has completed the requirements of the Pharmacy Technicians Certificate for external use , in relation to any medicine or related product, means for application to the anal canal, ear, eye, mucosa of the mouth, nose, skin, teeth, throat, or vagina, where local action only is required and where extensive systemic absorption will not occur; but nothing in these regulations relating to medicines or related products intended for external use shall apply to nasal drops, nasal inhalations, nasal sprays, teething applications, throat lozenges, throat pastilles, throat sprays, or throat tablets general sale medicine has the meaning given to it by section 99(2) of the Act Pharmacy Council means the Pharmacy Council established by section 114(5) of the Health Practitioners Competence Assurance Act 2003 armacy graduate means a person who is not a pharmacist, but who --  (a) has 1 or more of the qualifications prescribed by the Pharmacy Council under section 12(1) of the Health Practitioners Competence Assurance Act 2003 for registration as a pharmacist; and (b) is actively taking steps towards registration as a pharmacist armacy student means a person who is undertaking, but has not yet completed, the course and examinations leading to a qualification of a kind prescribed by the Pharmacy Council under section 12(1) of the Health Practitioners Competence Assurance Act 2003 armacy technician means any person who has a National Certificate in Pharmacy (Technician) armacy technician student means a person who is undertaking, but who has not yet completed, training and examinations leading to a National Certificate in Pharmacy (Technician) oison bottle means a container that is made of glass, plastic, or other like material, and that either --  (a) has embossed on at least one-third of its outer surface narrow flutings, ribs, nettings, or points, or other similar surface impressions readily recognisable by touch; or (b) has clearly embossed on 2 opposite sides of the shoulder of the container the word " POISON " in capital letters, the height of the letters being not less than half the width of that shoulder rincipal display panel means the part of a label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and, if such likelihood is equal in respect of 2 or more panels, means every such panel registered midwife means a health practitioner who is, or is deemed to be, registered with the Midwifery Council established by section 114(3) of the Health Practitioners Competence Assurance Act 2003 as a practitioner of the profession of midwifery safety container means a container, whether or not part of a strip of containers, that --  (a) encloses a single tablet or other single item of a medicine that is a solid or a class of medicines that are solids (including a medicine or class of medicines in powder form); and (b) is made of aluminium foil or laminated plastic, or such other material as may be approved by the Director-General in relation to the packaging of any solid medicine to which regulation 37 applies, either by notice in the Gazette or in writing addressed to a particular manufacturer, packer, importer, or seller of medicines; and (c) is reasonably resistant to attempts by young children to open it specified publication means a publication named in section 108(1) of the Act student means a pharmacy student or a pharmacy technician student. (2) In these regulations, unless the context otherwise requires, all references to proportions in a medicine (whether as percentages, parts per million, or otherwise) shall be references to --  (a) proportions by weight, where the medicine is a solid; or (b) proportions by volume, where the medicine is a liquid at ambient temperatures. Part 2 Standards (1) Any medicine or related product, other than a medicine or related product for which a standard is otherwise prescribed in these regulations, shall, where it is described as conforming to a monograph in a specified publication, conform to the description and tests set out in that publication for that medicine or related product. (2) Every medicine, related product, or cosmetic used or represented as suitable for application into the eye shall conform to the tests for sterility set out in a specified publication. (3) Every medicine, related product, or cosmetic that is a dusting powder for use on the skin of a baby, or on any inflamed, abraded, or broken skin, shall be free of pathogenic organisms. (4) No medicine, related product, cosmetic, or dentifrice intended for sale shall contain or have attached to it or enclosed with it any extraneous thing that is harmful, dangerous, or offensive. (5) A surgical dressing that is described as conforming to a monograph in a specified publication shall conform to the description and tests set out in that publication for that surgical dressing. (6) A medical device that is described as conforming to a particular description shall conform to that description. 5 Pharmacist may dilute medicine in particular case Where any liquid medicine in respect of which a standard is prescribed by any of the provisions of these regulations is to be supplied by a pharmacist pursuant to a prescription issued for a particular patient, the pharmacist may add a compatible diluent to the medicine if he is satisfied that --  (a) such dilution is necessary to adjust the dose to a quantity easily measurable by the patient or by any other person on behalf of the patient; and (b) the addition of that diluent will not affect injuriously the composition of the medicine. 6 Colouring substances Part 3 Advertisements 7 Advertisements not to claim official approval No advertisement relating to any medicine, related product, or medical device shall contain a statement to the effect that an advisory or technical committee established under section 8 of the Act, or any member of such a committee, or any officer in the service of the Government, has approved, or has refrained from disapproving, the advertisement or any of the claims or statements made in it. 8 Advertisements for medicines (1) Every advertisement for a prescription medicine must include --  (a) the words " Prescription medicine " or words of a similar meaning; and (b) the name of each active ingredient; and (c) the appropriate quantitative particulars of each active ingredient; and (d) a statement of the purpose for which the medicine is intended to be used; and (e) a statement that the medicine has risks and benefits; and (f) a statement about how to find further information on the risks and benefits of the medicine. (iii) the appropriate quantitative particulars of each active ingredient; and (iv) a statement of the purpose for which the medicine is intended to be used; and (v) a statement of the appropriate precautions to be taken in the use of the medicine; and (vi) information on the effectiveness and limitations of the medicine; and (vii) a statement of any restriction imposed on distribution; and (viii) the dosage regime and mode of administration, or method of use, of the medicine; and (ix) a statement of any contraindications to the use of the medicine; and (x) information on the likely potentiating effects and interactions with other substances, medicines, or environmental influences; and (xi) a statement of the known or likely poisonous effects of, or adverse reactions to, the medicine; but (b) not include --  (i) a statement (based on the citation of a report) relating to the effectiveness or safety of the medicine that omits relevant parts of the report, or quotes from the report in such a way that another meaning to that intended by the report is conveyed; or (ii) an unsubstantiated comparison with other medicines; or (iii) data, previously considered valid, but made obsolete or false by subsequent findings; or (iv) a statement of the use of the medicine, or the dosage of the medicine, that contravenes any condition of a consent given under section 20 , 23 , or 24 of the Act. (3) Nothing in subclause (2)(a)(iii) or (vi) to (xi) applies to an advertisement that --  (a) is intended to provide a practitioner with details of --  (i) a major therapeutic indication of a medicine; or (ii) the listing of a medicine in the pharmaceutical schedule (within the meaning of section 6(1) of the New Zealand Public Health and Disability Act 2000); or (iii) a new or changed strength of a medicine; and (b) does not enable the practitioner to reach a prescribing decision. (4) Every advertisement for a related product or medical device must include --  (a) a statement of any restriction imposed on distribution; and (b) the dosage regime and mode of administration, or method of use, of the related product or medical device; and (c) information on the effectiveness and limitations of the related product or medical device. Part 4 Labelling 12 Medicines, related products, and medical devices not to be sold unless properly labelled (1) No person shall sell any medicine or related product in a container if the container --  (a) does not bear a label containing all the particulars required by these regulations to be on a label relating to such a container; or (b) bears a label containing anything that is prohibited by these regulations from appearing on a label relating to such a container; or (c) bears a label containing any particulars that are not in the position, manner, and style required by these regulations in respect of a label relating to such a container. (2) No person shall sell a package containing a single container of any medicine or related product unless that package is labelled in a manner similar to that in which the container is labelled. (3) No person shall sell any medicine in a poison bottle bearing any label that obscures any flutings, ribs, nettings, points, embossed words, or similar markings on the bottle. (4) No person shall sell any medical device that does not bear the name of the manufacturer of the medical device or the name of the manufacturer's distributor in New Zealand. (5) Notwithstanding anything in the foregoing provisions of this regulation, the Director-General may, by notice in writing to the manufacturer or importer of any medicine, exempt from the labelling requirements of these regulations the sale of that medicine in a container of a specified type. 13 Labelling of medicines (1) Every container of a medicine must, unless otherwise provided by these regulations, bear a label containing the following information: (a) the trade name of the medicine or, if there is no trade name, the appropriate designation of the medicine: (b) the name of each active ingredient: (c) the appropriate quantitative particulars of each active ingredient: (d) a description of the medicine, including dose form, or presentation, that indicates the true nature of the medicine: (e) a statement of the net weight or volume or number of the contents of the container, as the case may require: (f) in the case of a prescription medicine, --  (i) the words " PRESCRIPTION MEDICINE " or words of a similar meaning; or (ii) the words " PRESCRIPTION-ONLY MEDICINE " or words of a similar meaning; or (iii) the acronym " POM " : (g) in the case of a restricted medicine, --  (i) the words " RESTRICTED MEDICINE " ; or (ii) the words " PHARMACIST-ONLY MEDICINE " : (h) in the case of a pharmacy-only medicine, --  (i) the words " PHARMACY-ONLY MEDICINE " or words of a similar meaning; or (ii) the words " PHARMACY MEDICINE " or words of a similar meaning: (i) any warning statement required by these regulations for the medicine: (j) in the case of a medicine other than a prescription medicine, a statement of the purpose for which the medicine is intended to be used: (k) in the case of a medicine sold, or intended for sale, for external use, --  (i) a statement of directions for use and frequency of use; and (ii) the words " Caution: not to be taken " , or " For external use only " , or words of a similar meaning: (l) in the case of a medicine sold, or intended for sale, for internal use, --  (i) the dose recommended; and (ii) the frequency of that dose: (m) the words " Batch Number " or " Lot Number " , or the word " Batch " or " Lot " , or the letter " B " (either alone or inside a circle) followed by the batch or lot number of the medicine: (n) the words " Use by " or " Use before " , or words of a similar meaning, followed by the expiry date (being in no case later than 5 years after the date of manufacture of the medicine) appropriate to the stability of the medicine: (o) where appropriate, a statement of the recommended storage conditions: (p) the name and address of --  (i) the manufacturer or seller of the medicine; or (ii) the owner of the rights of manufacture; or (iii) the agent of any person who comes within subparagraph (i) or (ii). (2) For the purposes of subclause (1)(p), --  (a) an address at a post office is not sufficient: (b) the name and address of a person not ordinarily resident in New Zealand are not sufficient unless the medicine is wholly manufactured and packed outside New Zealand: (c) in the case of a body corporate registered in New Zealand, the name of the town in which the body corporate has its registered office is sufficient. (3) In the case of a medicine intended for administration only in accordance with the directions of a practitioner, it is sufficient compliance with subclause (1)(l) to indicate the dose by a range if the container is accompanied by a more specific statement relating to each usage. (4) In the case of a prescription medicine, compliance with the requirements of subclause (1)(k) or (l) is required only at the time at which that medicine --  (a) is sold by retail; or (b) is supplied in circumstances corresponding to retail sale; or (c) is supplied by way of gift or sample for the purpose of promoting a sale. (5) Subclause (1)(l) does not apply in the case of a medicine intended to be administered by or under the supervision of a practitioner, in circumstances where the dosage is to be dependent on concurrent skilled observation. (6) Every container of a medicine that is prepared for injection into the human body and that contains an antiseptic or preservative must be labelled with a statement of the nature and amount of the antiseptic or preservative. (7) Every container of a medicine that is a biochemical preparation must, in addition to the other requirements in this regulation, bear a label containing the following: (a) a statement of the potency of the preparation; and (b) a statement of the nature and amount of every antiseptic or preservative (if any) used in the medicine. (8) Where it is impractical to put all of the information required by this regulation on a label because the container is too small, it is sufficient compliance with this regulation to print the information required by subclause (1)(i), (j), and (o) on a separate information sheet, in the same manner as that information would be required by these regulations to be printed on a label, and to supply that sheet to the customer with the medicine. (A) at least once in relation to every 2 containers, if the containers are easily detached from the strip; and (B) at least once on the strip in any other case; and (c) is contained in a package that complies with regulation 13 or 14 (as the case requires); and (d) is not intended for sale other than in that package. (3) In this regulation, strip of containers means a series of containers that each contain a single dose of a medicine or related product and that together form a strip. (4) Nothing in regulation 13(1)(f), (g), or (h) applies to a prescription medicine, restricted medicine, or pharmacy-only medicine, held for sale by a manufacturer or wholesaler, for the period of 3 months immediately following the date on which it becomes a prescription medicine, restricted medicine, or pharmacy-only medicine (as the case may be) if, at that date, the medicine was part of the existing stock-in-trade in New Zealand of the manufacturer or wholesaler. (5) Nothing in regulation 13(1)(f), (g), or (h) applies to a prescription medicine, restricted medicine, or pharmacy-only medicine, held for sale by a retailer, for the period of 6 months immediately following the date on which it becomes a prescription medicine, restricted medicine, or pharmacy-only medicine (as the case may be) if, at that date, the medicine was part of the existing stock-in-trade in New Zealand of the retailer. (6) For the purposes of subclauses (4) and (5), any goods purchased before the date on which a substance becomes a prescription medicine, restricted medicine, or pharmacy-only medicine (as the case may be) for importation into New Zealand are deemed to be part of the purchaser's stock-in-trade in New Zealand. (7) In any proceedings for an offence against section 44 of the Act in respect of any container that does not comply with regulation 13(1)(f), (g), or (h) , the onus is on the defendant to prove that the relevant paragraph does not apply by virtue of subclause (4) or (5) of this regulation. 17 Form and manner of labelling (1) Subject to subclause (4), every label that is required by these regulations to be borne on a container shall --  (a) be conspicuously written in English and, for each statement separately required, be in a colour or colours contrasting strongly with the statement's background; and (b) be legibly and durably marked either on the material of the container or on material firmly and securely attached to the container; and (c) be of such nature and material that it will not fade to the extent of becoming illegible, or become detached, by the influence of --  (i) light; or (ii) atmospheric humidity or dryness; or (iii) normal atmospheric temperatures; or (iv) recommended storage temperatures; or (v) the contents of the container; and (d) be of such a nature and in such a position that it will not readily be defaced in the course of normal handling and use; and (e) be in such a position that it is not damaged, defaced, destroyed, or removed when the container is opened; and (f) not be obscured by any other label, folder, or pamphlet; and (g) [Revoked] (2) The lettering of the words required by these regulations shall be clear, distinct, and legible, with no decoration, embellishment, or distortion that could interfere with the legibility of the words. (3) Every label that is required by these regulations to appear on a container shall, if the medicine or related product is sold otherwise than in a container, appear on the medicine or related product. (4) It shall be sufficient compliance with subclause (1) if the particulars required by paragraphs (d) and (e) of regulation 13(1) are embossed conspicuously on the container of the medicine. 18 Size of letters (1) A minimum size of lettering used on labels that is prescribed by these regulations refers to the height of capital letters, or lower case letters with an ascender or descender, in the typeface used. (2) [Revoked] (3) [Revoked] (4) [Revoked] (5) Subject to subclause (6) and except as otherwise expressly permitted by any of the provisions of these regulations, the lettering of words required by these regulations to appear on labels shall be not less than 1.5 millimetres in height. (6) Where words are required by these regulations to appear on labels in letters of a specified size, and the container to be labelled is so small as to prevent the use of letters of that size, letters of a smaller size may be used if they are of the largest size practicable in the circumstances and are in any event no smaller than 0.75 millimetres. 23 Labels on containers of medicines sold by authorised prescribers or pharmacists It shall not be necessary to comply with the requirements of regulation 13 or regulation 16(1) or regulation 22 in respect of any label on a container of a medicine that is packed, supplied, or sold by an authorised prescriber or a pharmacist with reference to the needs of a particular patient or (as the case may be) a particular customer, if the label contains the following: (a) the name of, or a description of the nature of, the contents; and (b) the name of the patient; and (c) the name and address of the seller; and (d) in the case of a medicine for internal use, the dose and frequency of dose; and (e) in the case of a medicine for external use, a statement of the directions for use and frequency of use, and one or other of the following statements, or words of similar meaning: " Caution: Not To Be Taken " , or " For External Use Only " ; and (f) a unique identifying number or code for the prescription or record of supply; and 24 Labels on containers of hair dyes (1) This regulation applies to labels on containers of related products and cosmetics that are intended for dyeing hair and consist of or contain --  (a) phenylenediamine, or its salts; or (b) toluenediamine, or its salts; or (c) other aromatic amines intended for dyeing hair, or their salts; or (d) any derivative of any substance to which paragraph (a) or paragraph (b) or paragraph (c) applies. (2) Every label to which this regulation applies shall include the following: (a) the name or description of the dye substance: (b) the name and address of the manufacturer or (as the case may be) the packer or seller of the related product or cosmetic: (c) directions for the use of the related product or cosmetic: (d) one or other of the following statements, or words of similar meaning: " Not To Be Taken " , or " For External Use Only " : (e) the following statement, or words of similar meaning: " May cause serious inflammation of the skin. Do not use on eyelashes " . 25 Misleading statements (1) No written, pictorial, or other descriptive matter appearing on or attached to or supplied or displayed with any medicine or medical device shall include any comment on, reference to, or explanation of any statement or label required by these regulations to be borne on any medicine or medical device if that comment, reference, or explanation either directly or by implication contradicts, qualifies, or modifies that statement or the contents of that label. (2) No written, pictorial, or other descriptive matter supplied or displayed with any medicine or medical device shall include any false or misleading statement, word, brand, picture, or mark purporting to indicate the nature, suitability, quantity, quality, strength, purity, composition, weight, origin, age, effects, or proportion of the medicine or medical device or any ingredients of the medicine or components of the medical device. Part 5 Manufacture, packing, storage, and handling 26 Persons handling medicines, related products, and cosmetics (1) Every person who --  (a) is engaged or employed in the manufacture, packing, labelling, storage, or supply of any medicine, related product, or cosmetic for sale; and (b) in the course of his engagement or employment in that activity comes into direct contact with --  (i) any medicine, related product, or cosmetic; or (ii) the interior part of any container containing any medicine, related product, or cosmetic; or (iii) a wrapper for any medicine, related product, or cosmetic --  shall, at all times while so engaged or employed, maintain his clothing and his person in a state of cleanliness. (2) No person who is engaged or employed in the sale of any medicine, related product, or cosmetic, or in the manufacture, packing, labelling, storage, or supply of any medicine, related product, or cosmetic for sale, shall do any act or make any default or omission whereby that medicine, related product, or cosmetic becomes or is liable to become contaminated, polluted, or tainted. 27 Infected persons No person who is suffering from a communicable disease (within the meaning of the Health Act 1956 ), or is a carrier (within the meaning of that Act), or is suffering from a condition causing a discharge of pus or exudate, shall engage or be employed in the sale, or the manufacture, packing, labelling, storage, or supply, for sale, of --  (a) any medicine, related product, or cosmetic; or (b) any material or article used or likely to be used as a wrapper or container for any medicine, related product, or cosmetic. 28 Persons in contact with infected persons (1) The Medical Officer of Health may, by notice in writing served on a person who has been in recent contact with any person to whom regulation 27 applies, prohibit the person so served from engaging or being employed in the sale of any medicine, related product, or cosmetic, or the manufacture, packing, labelling, storage, or supply of any medicine, related product, or cosmetic for sale. (2) Where, in the opinion of the Medical Officer of Health, there is no longer any risk of any medicine, related product, or cosmetic becoming infected by a person on whom any such notice has been served, the Medical Officer of Health shall revoke the notice, and shall notify the person in writing of the revocation. (3) No person shall --  (a) engage or undertake employment in any activity in contravention of a notice served on him under this regulation; or (b) knowingly employ any other person in contravention of a notice served on that other person under this regulation. 29 Places of manufacture, storage, and sale No person shall use any place or permit any place to be used for or in connection with the sale of any medicine, related product, or cosmetic, or the manufacture, storage, or packing of any medicine, related product, or cosmetic for sale, unless the place complies with the following requirements: (a) the place shall be kept adequately lighted by daylight or artificial light, as the circumstances require, at all times when any work is being carried out there: (b) the place shall be kept appropriately ventilated at all times while any medicine, related product, or cosmetic, or any container or material for the packing of any medicine, related product, or cosmetic, is present there: (c) if a waste liquid is produced there, the place shall be provided with a means of drainage that is sufficient for the removal of the waste liquid, and that is kept in good, clean, working order and condition: (d) the place shall be kept, so far as is practicable, clean and free from foul odours and free from dust and creatures likely to contaminate the medicine, related product, or cosmetic: (e) the walls, floors, ceilings, and roofs shall be properly constructed and kept in good repair, and shall be easy to clean: (f) the place shall not be used for any purpose (other than the sale of any medicine, related product, or cosmetic, or the manufacture, storage, or packing of any medicine, related product, or cosmetic for sale) that might affect the quality of the medicine, related product, or cosmetic: (g) the place shall be provided with sinks and other sanitary fittings reasonably necessary for cleansing appliances used there, and all such sinks and other sanitary fittings shall be maintained in good, clean working order and condition: (h) the place shall be provided with an adequate supply of hot and cold water, and soap or other detergent: (i) the place shall be provided adequately with wash basins and toilets for the use of persons engaged or employed in or about the premises, and all such wash basins and toilets shall be maintained in good, clean working order and condition, and shall be provided with an adequate supply of hot and cold water, soap or other detergent, nail brushes, and towels or other drying equipment. 30 Dwellinghouses prohibited for manufacture and packing No person shall use any dwellinghouse, or permit any dwellinghouse to be used, for or in connection with the manufacture or packing of any medicine, related product, or cosmetic for sale if the use of the dwellinghouse is likely to result in the contamination of the medicine, related product, or cosmetic, or to affect injuriously its cleanliness. 31 Powers of Medical Officer of Health in respect of premises (1) This regulation shall apply to premises that are, in the opinion of the Medical Officer of Health, by reason of their construction or disrepair, or by reason of the use or character of any neighbouring premises, in such a condition that any medicine, related product, or cosmetic in the first premises may be exposed to contamination or taint, or may deteriorate or become dirty. (2) Subject to subclause (6), the Medical Officer of Health may serve a notice in writing on any owner or occupier of any premises to which this regulation applies, prohibiting the use of the premises for or in connection with the manufacture, storage, or packing of any medicine, related product, or cosmetic for sale. (3) Every such notice shall --  (a) specify the premises to which it relates: (b) state the reason for the prohibition: (c) specify a date on which the prohibition is to come into force. (4) Subject to subclause (6), where in the opinion of the Medical Officer of Health the reason for which any such notice was served has ceased to exist, he shall revoke the notice, and shall notify in writing the owner or occupier of the premises concerned, and every other person on whom a copy of the notice has been served, of the revocation. (5) While any such notice remains in force, --  (a) no person on whom it has been served shall use or permit the use of the premises specified in the notice for or in connection with the manufacture, storage, or packing of any medicine, related product, or cosmetic for sale; and (b) no person on whom a copy of the notice has been served or who knows the contents of the notice shall use those premises for any such purpose. (6) No notice shall be served by a Medical Officer of Health pursuant to subclause (2) or subclause (4) unless approval to serve the notice has first been obtained from the Director-General. 32 Storage of medicines, etc (1) Every person in possession or control of any medicine, related product, or cosmetic for sale, or of any container or appliance used for or in connection with the sale of any medicine, related product, or cosmetic, or the manufacture, storage, or packing of any medicine, related product, or cosmetic for sale, shall at all times --  (a) keep the medicine, related product, cosmetic, container, or appliance clean and free from contamination by moisture, foul odours, or dust; and (2) Every person in possession of any medicine, related product, or cosmetic for sale shall at all times store and keep it packed in such manner as to minimise its deterioration, and shall comply with all requirements for storage stated on the label or contained in a specified publication in respect of that medicine, related product, or cosmetic. 33 Construction and use of containers, etc (1) No person shall use, or permit to be used, any container, appliance, or vehicle for or in connection with the manufacture, storage, packing, or supply of any medicine, related product, or cosmetic for sale unless that container, appliance, or vehicle is constructed of such material and in such manner as to allow for easy cleaning, and is kept clean. (2) No person shall use, or permit to be used, in the supply of any medicine, related product, or cosmetic for sale any container, appliance, or vehicle that is also used for the carriage of any matter that endangers or could endanger the cleanliness or freedom from contamination of the medicine, related product, or cosmetic. (3) No person shall use, or permit to be used, for the manufacture, storage, or packing of any medicine, related product, or cosmetic for sale, any container that has been used for any purpose that may contaminate or taint the medicine, related product, or cosmetic, unless the container has been thoroughly cleaned. 34 Exposure to toxic substances prohibited Except as otherwise provided in these regulations, no person shall, in the course of the manufacture, storage, packing, or supply of any medicine, related product, or cosmetic for sale, keep, carry, spread, or use, or permit to be kept, carried, spread, or used, any toxic or noxious substance so as to expose the medicine, related product, or cosmetic to the risk of contamination by that substance at any time. 35 Containers for medicines, related products, and cosmetics (1) A person must not pack, store, or sell a prescription medicine, restricted medicine, or pharmacy-only medicine in a container made of paper; but nothing in this subclause prevents the person from packing, storing, or selling the medicine in a container made of cardboard. (2) [Revoked] (3) No person shall use, or permit to be used, in the storage, packing, or supply of any medicine, related product, or cosmetic for sale, a container that yields, or could yield, to its contents a toxic, injurious, or tainting substance. (4) Every container used in the packing of a medicine and made of glass or plastic shall comply with the tests for that type of container (if any) specified in the United States Pharmacopeia . (5) Every container used in the packing of a medicine and made of metal shall be impermeable to moisture. (6) Every container used in the packing of a medicine and made of metal or plastic shall be made of a material that will not adversely react with the contents of the container. (7) Except as provided in subclause (8), no person shall store, pack, or sell in a container of a capacity of not less than 15 millilitres and not more than 2.5 litres any medicine, related product, or cosmetic that --  (a) is in liquid form; and (b) is intended for external use; and (c) has poisonous properties, --  unless the container is a poison bottle. (8) It shall not be necessary to pack in a poison bottle any medicine, related product, or cosmetic to which subclause (7) applies if that medicine, related product, or cosmetic is --  (a) supplied to or held for use in educational establishments, or in scientific or industrial laboratories; or (b) supplied to or held by analysts, pharmacists, authorised prescribers, or veterinary surgeons; or (c) supplied to or held by persons engaged as suppliers to any of the establishments, laboratories, or classes of persons mentioned in paragraphs (a) and (b); or (9) No person shall have in his possession or charge (whether for the purposes of sale or otherwise) in an open container, any medicine, related product, or cosmetic that has poisonous properties, except while the container is being filled or the medicine, related product, or cosmetic in the container is being used. (10) No person in possession or charge of any medicine, related product, or cosmetic shall keep it, whether temporarily or permanently, in any bottle, jar, can, tinplate container, culinary utensil, or other container of a type that --  (a) bears any brand, mark, statement, or picture that indicates the presence in the container of any food, drink, or condiment; or (b) is of a distinctive type in which any food, drink, or condiment, has been commonly or is being currently sold, whether or not the container bears any brand, mark, statement, or picture. 36 Storage to be separate No person shall store or keep for ready use any medicine, related product, or cosmetic in such manner that a food or drink may be contaminated by the escape or leakage of the medicine, related product, or cosmetic, or by the release of vapours from the medicine, related product, or cosmetic. 37 Safety containers (1) No person shall sell any tablet, or other single item in solid form that is intended to be taken orally, being or comprising a medicine or belonging to a class of medicines to which this regulation applies, unless the tablet or item is enclosed in a safety container. (2) Subclause (1) shall not apply --  (a) where an authorised prescriber directs, either on the prescription or otherwise, --  (i) that a medicine is not to be sold enclosed in a safety container; or (ii) that he or she does not wish the name of the medicine to appear on the label; or (b) where a pharmacist is of the opinion that, because of the age or infirmity of a particular person, a medicine to be used by that person should not be enclosed in a safety container; or (c) in the case of capsules, pills, powder, or other solid dose forms, prepared in a pharmacy with reference to the particular needs of a patient. (3) [Revoked] (4) This regulation applies to the following medicines: aspirin, and its salts; and medicines containing aspirin or its salts: iron, in medicines for human use containing more than 24 milligrams of elemental iron per dose: aracetamol; and medicines containing paracetamol. (5) This regulation applies to the following classes of medicines: barbiturates: enothiazine, and derivatives of phenothiazine and their salts, except dimethothiazine, methdilazine, promethazine, and trimeprazine, and their salts and molecular compounds: Part 6 Importation and transport 38 Containers (1) Every medicine imported into, or packed or consigned for transport in, New Zealand shall be securely packed in a container that is sufficiently strong to withstand, and to protect the contents from damage arising in, the ordinary course of transport. (2) No person shall import into, or transport or cause to be transported in, New Zealand any medicine that is not packed in compliance with subclause (1). (3) Every related product packed or consigned for transport in New Zealand shall be securely packed in a container that is sufficiently strong to withstand, and to protect the contents from damage arising in, the ordinary course of transport. (4) No person shall transport or cause to be transported in New Zealand any related product that is not packed in compliance with subclause (3). Part 7 Prescriptions 39 Conditions under which authorised prescribers and veterinarians may prescribe prescription medicines (1) An authorised prescriber (including a designated prescriber) may only prescribe a prescription medicine if the authorised prescriber --  (a) is prescribing the prescription medicine --  (i) for the treatment of a patient under the authorised prescriber's care; and (ii) within, and in accordance with all conditions (if any) stated in, the authorised prescriber's scope of practice, as determined by an authorisation granted under section 21 of the Health Practitioners Competence Assurance Act 2003 by the authority responsible for the registration of the authorised prescriber; and (b) is not prohibited by a notice under section 48(1) of the Act from prescribing that prescription medicine or any prescription medicines of a class or description that includes that prescription medicine. (2) An authorised prescriber who is a designated prescriber may only prescribe a prescription medicine if --  (a) the prescription medicine is of a class or description that the designated prescriber is authorised to prescribe by regulations made under the Act; and (b) the requirements specified in or imposed under those regulations are satisfied. (3) A veterinarian may only prescribe a prescription medicine that is for the treatment of an animal under the veterinarian's care. (4) Subclause (1) does not apply to an authorised prescriber who is acting in the course of his or her employment by the Crown. 39A Limit on period of supply of prescription medicines (1) An authorised prescriber may not on any occasion prescribe for any patient a quantity of any prescription medicine that exceeds --  (a) 6 months' supply in the case of an oral contraceptive; or (b) 3 months' supply in any other case. (2) However, the Director-General may, at his or her discretion, authorise --  (a) an authorised prescriber to prescribe for any patient, or any specified class or classes of patients, a quantity of a prescription medicine exceeding the period of supply in subclause (1)(a) or (b): (b) a class of authorised prescribers to prescribe for any patient, or any specified class or classes of patients, a quantity of a prescription medicine exceeding the period of supply in subclause (1)(a) or (b). 40 Prescriptions to comply with regulations (1) Except as provided in regulation 40A , every authorised prescriber or veterinarian who issues a prescription to a person must comply with regulation 41 . (2) Subclause (1) applies to a prescription for any medicine (whether a prescription medicine or not). (3) Subclause (2) does not prevent the sale by retail, or the supply in circumstances corresponding to retail sale, or the dispensing, of a medicine (other than a prescription medicine) without a prescription. 40A Urgently required prescriptions of prescription medicines may be communicated orally if later confirmed in writing (1) Where an authorised prescriber or veterinarian finds it necessary to do so, he or she may communicate orally to a pharmacist to whom he or she is known personally (whether in the pharmacist's presence or by speaking to the pharmacist on the telephone) a prescription relating to a prescription medicine that the authorised prescriber or veterinarian requires urgently. (2) Within 7 days after a communication made by an authorised prescriber or veterinarian to a pharmacist under subclause (1), the authorised prescriber or veterinarian must forward to the pharmacist a written prescription confirming the oral communication. 42 Dispensing of prescription medicines (1) Except as provided in subclause (2), no person other than an authorised prescriber, veterinarian, pharmacist, pharmacy graduate, a pharmacy technician, a student, or dispensary technician may dispense a prescription medicine. (1A) The following persons may not dispense prescription medicines unless under the direct personal supervision of a pharmacist: (a) dispensary technicians: (b) pharmacy graduates: (c) pharmacy technicians: (d) students. (2) An agent or employee of a veterinarian may, in any particular case, dispense any prescription medicine at the direction of the veterinarian for use in the treatment of any animal under the care of the veterinarian. (3) Every person dispensing a prescription relating to a prescription medicine must comply with the following requirements: (a) if the prescription has been communicated orally under regulation 40A(1) , the prescription must not be dispensed on more than 1 occasion before the pharmacist has received the written confirmation of the prescription, as required by regulation 40A(2): (b) the following information must be recorded on the prescription: (i) the name and address of the proprietor of the business at which the prescription is dispensed; and (ii) the date on which the prescription is dispensed; and (iii) the quantity of medicine dispensed; and (iv) a unique identifying number or code for the prescription: (c) a prescription for a medicine other than an oral contraceptive must not be dispensed on any occasion after 6 months have elapsed from the date on which it was printed or, if given under regulation 40A(1) , communicated orally: (d) a prescription for a medicine that is an oral contraceptive must not be dispensed on any occasion after 9 months have elapsed from the date on which it was printed or, if given under regulation 40A(1) , communicated orally: (e) every prescription must be retained for a period of 3 years by the pharmacist on the premises on which it was dispensed or at a place approved by the Medical Officer of Health and must be kept in an orderly and consecutive manner so as to be readily available for inspection. (4) If an authorised prescriber or a veterinarian refers in a prescription to a medicine by its trade mark or trade name, or by reference to the name of its manufacturer, a pharmacist may supply an alternative brand of medicine, provided that --  (a) the authorised prescriber or veterinarian has not marked the prescription " No brand substitution permitted " or with words of similar meaning; and (b) the substituted brand contains the same active ingredient or active ingredients, and no other active ingredients; and (c) the substituted brand is in the same dose form and strength as the prescribed brand; and (d) there is no clinical reason why the substituted brand should not be supplied; and (e) the pharmacist records the brand substitution on the prescription; and 43 Director-General may waive certain requirements (1) Despite the requirements in regulations 41 and 42 , the Director-General may, at his or her discretion, --  (a) authorise a form of prescription that does not comply with all or any of the requirements in regulation 41 , but that is subject to any other requirements that he or she thinks fit; and (b) authorise the dispensing of prescription medicines in a manner that does not comply with all or any of the requirements in regulation 42 , but that is subject to any other requirements that he or she thinks fit. (2) A form of prescription that may be authorised under subclause (1)(a) includes, but is not limited to, an electronic form of prescription. 44 Prescriptions for prescription medicines not required in certain cases A prescription medicine may be sold or dispensed otherwise than under a prescription given by a practitioner, registered midwife, veterinarian, or designated prescriber if it is sold to or dispensed for --  (a) a person licensed to sell the prescription medicine by wholesale; or (b) a person obtaining the prescription medicine for use in any process of manufacture or trade not involving the resale of the medicine; or (c) an analyst under the Act, or a person approved by the Director-General and in charge of a laboratory maintained for the purposes of research, study, or analysis; or (d) a hospital care operator within the meaning of section 58(4) of the Health and Disability Services (Safety) Act 2001; or (e) a pharmacist in control of any pharmacy, or any dispensary in a hospital care institution within the meaning of section 58(4) of the Health and Disability Services (Safety) Act 2001; or (f) an authorised prescriber or veterinarian; or (fa) [Revoked] (fb) [Revoked] (g) a patient under his or her care by an authorised prescriber; or (ga) [Revoked] (gb) [Revoked] (h) a patient under the care of an authorised prescriber, provided that --  (i) the medicine is administered by a person who has been instructed by the authorised prescriber (either verbally or in writing) to do so; and (ii) the person administering the medicine records the administration in the patient's medical record; and (iii) the authorised prescriber records the instruction under subparagraph (i) in the patient's medical record; or (i) if the medicine is prescribed by rules under section 36(1)(e) of that Act; or (ii) at a time before the commencement of the first rules made under section 36(1)(e) of that Act, if the medicine is authorised or required by scales issued under section 138 or section 239 of the Shipping and Seamen Act 1952; or (ia) the master of a foreign ship within the meaning of the Maritime Transport Act 1994 , if the law of the State whose flag the ship is entitled to fly requires the master to carry the medicine; or (j) a person for inclusion in an emergency medical kit kept or to be kept for use in any vessel to which paragraph (i) does not apply, and is so sold or dispensed pursuant to an order signed by a Medical Officer of Health; or (k) the person in charge of an aircraft if the medicine is required to be carried on the aircraft as a condition of the issue of a certificate of airworthiness; or (l) a person for inclusion in an emergency medical kit pursuant to an order signed by a Medical Officer of Health for use in a place of a class approved by the Director-General; or (m) a person who has previously been supplied with the medicine on the prescription of an authorised prescriber for a particular condition, and is so sold or dispensed --  (i) by a pharmacist who is satisfied that the person requires an emergency supply of the medicine for that condition; and (ii) in an amount not exceeding the quantity reasonably required by that person for a period of 72 hours, or a minimum pack of a special container from which it is not practicable to dispense a lesser amount; or (n) any person by a veterinarian for the treatment of an animal under the care of the veterinarian; or (o) a person or body authorised to distribute, or a person authorised to administer, the prescription medicine in an approved immunisation programme. 44A Administration of vaccines in approved immunisation programmes (1) Any medical practitioner or other person who is authorised by the Director-General or a Medical Officer of Health in accordance with this regulation to administer, for the purposes of an approved immunisation programme, a vaccine that is a prescription medicine, may, in carrying out that immunisation programme, administer that prescription medicine otherwise than pursuant to a prescription. (2) The Director-General or a Medical Officer of Health may authorise any person to administer a vaccine for the purposes of an approved immunisation programme if that person, following written application, provides documentary evidence satisfying the Director-General or the Medical Officer of Health, as the case may be, that that person --  (a) can carry out basic emergency techniques including resuscitation and the treatment of anaphylaxis; and (b) has knowledge of the safe and effective handling of immunisation products and equipment; and (c) can demonstrate clinical interpersonal skills; and (d) has knowledge of the relevant diseases and vaccines in order to be able to explain the vaccination to the patient, or to the parent or guardian of the patient who is to consent to the vaccination on behalf of the patient, to ensure that the patient or the parent or guardian of the patient can give informed consent to the vaccination. (3) Subject to subclause (4), any authorisation given by the Director-General or a Medical Officer of Health under subclause (2) shall be valid for a period of 2 years and shall be subject to such conditions as the Director-General or the Medical Officer of Health, as the case may be, thinks fit. (4) An authorisation given to any person under subclause (2) may be withdrawn at any time before its expiry if the Director-General or a Medical Officer of Health is satisfied that the authorised person has failed to comply with any condition specified by the Director-General or the Medical Officer of Health under subclause (3). 44B Duty to supply information (1) The Medical Officer of Health may require any authorised prescriber to supply information relating to the prescribing, administering, or supplying of any prescription medicines if the Medical Officer of Health has reason to suspect that prescription medicines may have been improperly prescribed, administered, or supplied by the authorised prescriber. (2) Every requirement to supply information must be in writing, stating the reasons for the Medical Officer of Health's suspicion. (3) The information that must be supplied is information justifying the prescription, administering, or supply of the prescription medicines as follows: (a) the age of the patient: (b) the diagnosis of the patient's condition: (c) the prognosis of the patient's condition: (d) details of any specialist referral: (e) any alternative treatments considered or tried. (4) An authorised prescriber to whom any such notice is sent must supply the required information in writing to the Medical Officer of Health within 30 days. Part 7A Export of prescription medicines 44C No export of prescription medicines for retail sale without New Zealand prescription (1) No person may export a prescription medicine in the course or for the purpose of retail sale, otherwise than under a prescription given by a practitioner, a registered midwife, or a designated prescriber. (2) The meaning of retail sale in subclause (1) must be determined by reference to section 5(2) of the Act. (3) Subclause (1) is intended to limit the sale and supply of prescription medicines pursuant to section 33(b) of the Act. Part 7B Supply of restricted medicine and pharmacy-only medicine 44D Supply of restricted medicine and pharmacy-only medicine (1) A person may, in the course of any business carried on by that person, supply a restricted medicine or pharmacy-only medicine if he or she --  (a) is authorised to supply the medicine in accordance with a standing order; and (b) supplies that medicine in accordance with that standing order. (2) The circumstances in which a person may supply a restricted medicine or pharmacy-only medicine under subclause (1) are in addition to the circumstances in which a person may supply a restricted medicine or pharmacy-only medicine under section 18(1)(b) or (c) of the Medicines Act 1981. (i) the premises the applicant intends to use for the activity to which the application relates; or (ii) in the case of an application for a licence to hawk medicines, the area in which the applicant intends to operate: (d) specify the medicines, or the descriptions or classes of medicines, that the applicant proposes to manufacture, hawk, sell, or pack: (e) specify --  (i) the applicant's qualifications; or (ii) if the applicant is a body corporate, the qualifications of every person who will, if the application is successful, be a responsible person for the purposes of the licence to which the application relates: (f) in the case of an application for a licence to sell any medicine by retail or to hawk any medicine, be accompanied by a certificate of character that states that the applicant --  (i) is well known to the person giving the certificate; and (ii) is of good character; and (iii) is considered by the person giving the certificate to be a fit and proper person to be licensed to sell or hawk medicine. (2) A licence to undertake an activity referred to in subclause (1) may only be granted in respect of 1 place of business. (3) Despite subclause (2), the licensing authority may grant a licence that allows for the manufacture of medicine, or a description or class of medicines, at more than 1 place of business if --  (a) the application to which the licence relates is made by a body corporate; and (b) the licensing authority is satisfied that the body corporate has taken steps to ensure appropriate supervision of the manufacture of the product at each of the places of business. (4) Every applicant for a licence under this regulation must provide the licensing authority with the following things if required by the licensing authority under section 51 of the Act: (a) further information: (b) an opportunity to inspect the applicant's premises and equipment. (5) The licensing authority may, in order to determine if a person to whom section 51(1)(d) of the Act applies has a sufficient knowledge of the obligations of a licensee and of the hazards associated with the medicines to which a licence to manufacture, hawk, sell, or pack medicine relates, require that person to undertake and pass any oral, written, or practical tests that the licensing authority considers reasonably necessary in the particular case. (ii) a completed statutory declaration (as set out in the relevant form). (2) A licence to operate a pharmacy may only be granted in respect of 1 place of business. (3) Every applicant for a licence under this regulation must provide the licensing authority with the following things if required by the licensing authority under section 51 of the Act: (a) further information: (b) an opportunity to inspect the applicant's premises and equipment. (4) The licensing authority may, in order to determine if a person to whom section 51(1)(d) of the Act applies has a sufficient knowledge of the obligations of a licensee and of the hazards associated with the medicines to which a licence to operate a pharmacy relates, require that person to undertake and pass any oral, written, or practical tests that the licensing authority considers reasonably necessary in the particular case. 47 Licence to manufacture medicines (1) Every application for a licence to manufacture any medicine shall specify which of the following descriptions or classes the medicine comes within or belongs to: (a) antibiotics and preparations of antibiotics: (b) vaccines and sera: (c) sterile preparations: (d) hormones and steroid preparations: (e) preparations, other than vitamins, that have a dose of 5 milligrams or less per unit dose: (f) antineoplastic agents and immunosuppressant agents, other than steroid preparations: (g) other medicines. (2) Where an application to manufacture medicines applies to 1 or more medicines or descriptions or classes of medicines, the licensing authority may grant a licence for all the medicines or descriptions or classes of medicines to which the application relates, or for such of the medicines or descriptions or classes of medicines to which the application relates as the licensing authority is satisfied the applicant is qualified to manufacture and capable of manufacturing. 48 Licence to hawk certain medicines (1) Subject to subclause (2), and without affecting the generality of regulation 46(2) , every licence to hawk any prescription medicine, restricted medicine, or pharmacy-only medicine shall be granted subject to the following conditions: (a) the licence shall apply only to those medicines or descriptions or classes of medicine specified in the licence: (b) the licensee shall keep the stocks of medicines in a place approved by the licensing authority: (c) where the licensing authority imposes a limit on the quantity of medicines that may be carried by the licensee when hawking, the licensee shall not carry medicines in excess of that quantity: (d) the licensee shall hawk medicines only to those persons or classes of persons specified in the licence. (2) No person shall be granted a licence to hawk any prescription medicines, restricted medicines, or pharmacy-only medicines by retail. 48A Licensing authority to be advised of change in particulars relating to operating pharmacy (1) A company or person who is granted a licence to operate a pharmacy must advise the licensing authority as soon as practicable of any change in the details that relate to the application for that licence (including, without limitation, changes in the details of any additional information required by the licensing authority). (2) A company that is granted a licence to operate a pharmacy under section 55D(2)(a) of the Act must immediately advise the licensing authority if there is a change or are changes in the ownership of the share capital of the company that means that more than 50% of the share capital is no longer owned by a pharmacist or pharmacists. (3) The requirement imposed by subclause (2) is in addition to the requirement imposed by subclause (1). 49 Surrender of licence (1A) If this subclause applies, the licensee must, within 7 days of ceasing to undertake the activity to which the licence relates, surrender that licence to the licensing authority. (2) The licensing authority, on receiving a licence pursuant to subclause (1A), shall retain the licence for the remainder of the current licence period. (3) Nothing in this regulation shall prevent a licensee who has surrendered his licence pursuant to subclause (1A) from applying to the licensing authority for restoration of the licence to the licensee at any time during the current licence period. (4) In any such case, but subject to subclause (5), the licensing authority, on being satisfied that the licensee complies with the requirements of the Act and these regulations relating to the granting of licences, shall restore the licence to the licensee. (5) Notwithstanding anything in these regulations, it shall not be necessary for any licensee who surrenders his licence to pay a further licence fee on application for restoration of that licence. Part 9 Withdrawal of medicines, etc 50 Withdrawal of medicines, etc (1) The Director-General may issue to any importer, manufacturer, or seller of any medicine, related product, or medical device an order --  (a) directing the withdrawal from sale of any medicine, related product, or medical device in respect of which there is in force a notice given by the Minister under section 35 or section 37 of the Act, or of any portion of the produced quantity of any such medicine, related product, or medical device, if the Director-General believes on reasonable grounds that such withdrawal is necessary to protect the public; or (b) directing the withdrawal from sale of any medicine, related product, or medical device, or any portion of the produced quantity of any medicine, related product, or medical device, that does not conform to the specifications claimed for that medicine, related product, or medical device; or (c) requiring the disposal of any medicine or related product, or any specific quantity of a medicine or related product, that has been directed to be withdrawn under paragraph (a) or paragraph (b); or (d) requiring the disposal or destruction of any medical device, or any specific quantity of any medical device, that has been directed to be withdrawn under paragraph (a) or paragraph (b). (2) The importer, manufacturer, or seller shall, on receipt of an order made under subclause (1), advise the Director-General of the manner and time in which he proposes to comply with the order, and shall give written notice to the Director-General when the order has been complied with. (3) Notwithstanding anything in subclause (2), the Director-General may issue directions to the recipient of an order made under subclause (1) as to the manner and time in which the order is to be complied with. Part 10 Data sheets 51 Interpretation In this Part, unless the context otherwise requires, data sheet , in relation to a medicine, means a document containing information relating to the safe and effective use of the medicine. 52 Approval of data sheets for new medicines (1) A person who applies under section 20 or 23 of the Act for the consent of the Minister to the distribution of a prescription medicine or restricted medicine (an applicant ) must include with his or her application a proposed data sheet for the medicine in such form as may be required by guidelines issued from time to time by the Ministry of Health. (2) On receipt of the proposed data sheet, the Minister may --  (a) approve the data sheet; or (b) require the data sheet to be resubmitted for approval after such changes have been made to it as the Minister considers appropriate. (3) Within 10 days after the Minister's consent to the distribution of a prescription medicine or restricted medicine has been notified in the Gazette , the applicant must send to the Director-General for publication an electronic copy of the approved data sheet for that medicine. 53 Approval of data sheets for changed medicines (1) An importer or manufacturer who gives to the Director-General a notice under section 24(1) of the Act describing a material change to a prescription medicine or restricted medicine must include with the notice a proposed revised data sheet for the medicine in such form as may be required by guidelines issued from time to time by the Ministry of Health if a revision of the data sheet is necessary or desirable because of the material change. (2) On receipt of the proposed revised data sheet, the Director-General may --  (a) approve the revised data sheet; or (b) require the revised data sheet to be resubmitted for approval after such changes have been made to it as the Director-General considers appropriate. (3) After the Director-General has approved a revised data sheet, the Director-General must give written notice of the approval to the importer or manufacturer. (4) Within 10 days after receiving a notice of approval under subclause (3), the importer or manufacturer must send to the Director-General for publication an electronic copy of the approved revised data sheet. 55 Records of sales by retail or wholesale (1) Before giving to the buyer a medicine to whose sale regulation 54A(1) applies, the person making the sale must record in the Sale of Medicines Register maintained under regulation 54A(2) the information stated in regulation 54A(4). (2) It is not necessary to comply with subclause (1) in relation to a sale by wholesale if the information stated in regulation 54A(4) can be discovered from the seller's books and records. 56 Record of hawker's sales (1) Every person who hawks any prescription medicine, restricted medicine, or pharmacy-only medicine shall keep and maintain a " Hawker's Medicines " book that records the medicines that he hawks or has in his possession. (3) The particulars in the Hawker's Medicines book shall be legibly and indelibly entered not later than the ordinary business day next following the day on which the medicine concerned was sold. (4) Every person to whom subclause (1) applies shall --  (a) satisfy himself that the purchaser is entitled to the medicine; and (b) before selling the medicine to the purchaser, obtain from the purchaser a printed request for the medicine, signed and dated by the purchaser, that contains the following particulars: (i) the date of each transaction: (ii) the name of the purchaser: (iii) the address of the place of business or residence of the purchaser: (iv) the name of the medicine sold: (v) the quantity of the medicine sold. 57 Record of supplies pursuant to prescriptions (1) Every person who dispenses or supplies any prescription medicine or restricted medicine pursuant to a prescription shall, not later than the ordinary business day next following the day on which the medicine was dispensed or supplied, record that dispensing or supply of the medicine in a " Prescriptions " register, or in such other form, or within such other period of time, as the Director-General may from time to time approve. (a) the date of each transaction: (b) the name of the patient or (as the case may require) the owner of the animal: (c) the address of the patient or (as the case may require) the owner of the animal: (d) the name of the medicine supplied: (e) the quantity of the medicine supplied: (f) the name of the prescriber: (g) in the case of a prescription medicine, the unique identifying number or code of the prescription. 58 Records to be kept (1) The person responsible for a record to which this Part applies must keep it for at least 3 years after it was made (or, if it is kept together with other records, for at least 3 years after the most recent of them was made). 60 Certificate of analyst The certificate of an analyst given for the purposes of section 70 of the Act shall be in the form set out in Schedule 5 . 61 Fees (1) The licence fees set out in Schedule 5A are payable for the licences to which they relate. (2) The amount to be deposited with the Medicines Review Committee pursuant to section 13(2) of the Act shall be $9,000. (3) The fee to accompany an application made under section 21 of the Act for the Minister's consent under section 20 of the Act shall be $122,625 where any active ingredient of the medicine that is the subject of the application is not generally available as at the date of that application. (4) The fee to accompany any other application made under section 21 of the Act for the Minister's consent under section 20 of the Act shall be $43,875. (5) The fee to accompany an application made under section 21 of the Act (as applied by section 96(1) of the Act) for the Minister's consent under section 20 of the Act in relation to a related product shall be $5,500. (6) The fee to accompany an application made under section 23 of the Act for the Minister's provisional consent shall be $8,437. (7) The fee to accompany a notice deposited with the Director-General under section 24 of the Act shall be $3,200. (8) The fee to accompany an application made under section 30 of the Act for the approval of a clinical trial, and of the persons (in that section called investigators) who will conduct that trial, shall be $9,843. (9) For the purposes of section 70(4) of the Act, the fee for a copy of a certificate of an analyst, or (as the case may be) a copy of a report made by an analyst in respect of a sample, shall be $60. (10) For the purposes of section 97(1) of the Act, the fee for procuring a sample of any medicine and submitting it for analysis shall be $600. (11) For the purposes of subclause (3), not generally available means not legally available other than pursuant to an exemption granted under any or all of sections 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 32A , or 33 of the Act. 65 Appeals to District Court (1) Any occupier of premises in respect of which any decision has been made under regulation 31 by a Medical Officer of Health, may appeal against that decision to a District Court within 14 days after being notified in writing of the decision. (2) An appeal under this regulation shall be made by way of originating application in accordance with the District Courts Rules 2009 , and shall be filed in the office of the court nearest to the place of business or employment of the appellant. (3) On hearing an appeal brought under this regulation, the court may confirm, reverse, or modify the decision made by the Medical Officer of Health, and the decision of the court on the appeal shall be final. (1) Until 1 February 2012, it is sufficient compliance with the advertising requirements of regulations 8 and 11 to comply with regulations 8 and 11 as in force immediately before 1 August 2011. (2) For medicines and related products manufactured or imported before 1 September 2012, it is sufficient compliance with the labelling requirements of regulations 13 to 16 , 19 , 22 , 23 , and 37 to comply with regulations 13 to 16, 19, 20 , 22, 23, and 37 as in force immediately before 1 August 2011. Schedule 1 Prescription, restricted, and pharmacy-only medicines Every reference to a medicine in this schedule applies whether the medicine is synthetic in origin or is from biological or mineral sources. Unless specific reference is made otherwise, every reference applies also to medicines that are --   preparations and admixtures containing any proportion of any substance listed in this schedule:  salts and esters of any substance listed in this schedule:  preparations or extracts of biological materials listed in this schedule:  salts or oxides of elements listed in this schedule. Unless specific reference is made otherwise, every reference to a medicine in this schedule applies, --   if the medicine is an injection or eye preparation, to any concentration of that medicine; and  if the medicine is not an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram. Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol, or element unless specifically stated otherwise. Part 1 Prescription medicines Amending or replacing this Part may affect designated prescriber regulations under section 105(1)(q) of the Act. 1 19-norandrostenedione 2 2,4-dinitrochlorobenzene 3 4-aminopyridine 4 4-chloromethandienone 5 4-chlorotestosterone 6 Abacavir 7 Abatacept 8 Abciximab 9 Abrus precatorius; at all strengths 10 Acamprosate 11 Acarbose 12 Acebutolol 13 Acepromazine 14 Acetanilides 15 Acetarsol 16 Acetazolamide 17 Acetohexamide 18 Acetylcarbromal 19 Acetylcholine; except in medicines containing 1 milligram or less per litre or per kilogram 20 Acetylcysteine; for injection or inhalation 21 Acetyldigitoxin 22 Acetylmethyldimethyloximidophenylhydrazi\\... 23 Acetylstrophanthidin 24 Aciclovir; except for external use for the treatment of herpes labialis 25 Acipimox 26 Acitretin 27 Acokanthera ouabaio 28 Acokanthera schimperi 29 Aconitum spp.; except when specified elsewhere in this schedule 30 Acrivastine 31 Adalimumab 32 Adapalene 33 Adefovir 34 Adenosine; for injection 35 Adinazolam 36 Adiphenine 37 Adonis vernalis 38 Adrafinil 39 Adrenal extract; except for dermal use in medicines containing 0.02% or less of ketosteroids 40 Adrenaline; in medicines containing more than 1% 41 Adrenocortical hormones; except adrenal extract for dermal use containing 0.02% or less of ketosteroids 42 Agalsidase 43 Agomelatine 44 Alatrofloxacin 45 Albendazole 46 Albumin; except human albumin 47 Alclofenac 48 Alclometasone; except when specified elsewhere in this schedule 49 Alcohol; for injection in medicines containing more than 20% 50 Alcuronium 51 Aldesleukin 52 Aldosterone; except in medicines containing 10 micrograms or less per litre or per kilogram 53 Alefacept 54 Alemtuzumab 55 Alendronic acid 56 Alfacalcidol 57 Alfentanil 58 Alfuzosin 59 Alglucerase 60 Alglucosidase 61 Aliskiren 62 Alkyl sulfonals 63 Allergens 64 Allopurinol 65 Allylisopropylacetylurea; at all strengths 66 Allyloestrenol 67 Alosetron 68 Alpha 1 -proteinase inhibitor 69 Alphadolone 70 Alphaxalone 71 Alprazolam 72 Alprenolol 73 Alprostadil 74 Alseroxylon 75 Alteplase 76 Altretamine 77 Amantadine 78 Ambenonium 79 Ambrisentan 80 Ambucetamide 81 Ambutonium 82 Amcinonide 83 Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 84 Amfebutamone 85 Amfepramone 86 Amidopyrine 87 Amifostine 88 Amikacin 89 Amiloride 90 Aminocaproic acid 91 Aminoglutethimide 92 Aminometradine 93 Aminophenazone; at all strengths 94 Aminophylline; except for oral use in liquid form in medicines containing 2% or less 95 Aminopterin 96 Aminorex 97 Aminosalicylic acid 98 Amiodarone 99 Amiphenazole 100 Amisometradine 101 Amisulpride 102 Amitriptyline 103 Amlodipine 104 Ammi visnaga 105 Ammonium bromide 106 Amobarbital 107 Amodiaquine 108 Amorolfine; except for external use 109 Amoxapine 110 Amoxycillin 111 Amphomycin 112 Amphotericin 113 Ampicillin 114 Amprenavir 115 Amrinone 116 Amsacrine 117 Amygdalin; at all strengths 118 Amyl nitrite; except when sold to a person who holds a controlled substances licence (issued under section 95B of the Hazardous Substances and New Organisms Act 1996) authorising the person to possess cyanide 119 Amylocaine 120 Anabolic steroids 121 Anagrelide 122 Anakinra 123 Anastrozole 124 Ancestim 125 Anchusa officinalis; at all strengths 126 Ancrod and its immunoglobulin antidote 127 Androgenic and anabolic steroidal agents 128 Androgens 129 Androisoxazole 130 Androstanolone 131 Androstenediol 132 Androstenedione 133 Anecortave 134 Angiotensinamide 135 Anidulafungin 136 Anistreplase 137 Antazoline; except for ophthalmic use 138 Antibiotic substances; except when specified elsewhere in this schedule 139 Antigens 140 Antihistamines; except when specified elsewhere in this schedule 141 Antimony; except in medicines containing 1 milligram or less per litre or per kilogram 142 Antisera; for injection 143 Apocynum spp. 144 Apomorphine; except in medicines containing 1 milligram or less per litre or per kilogram 145 Apraclonidine 146 Aprepitant 147 Apronal 148 Aprotinin 149 Arecoline 150 Aripiprazole 151 Aristolochia spp.; at all strengths 152 Aristolochic acid; at all strengths 153 Arsenic; except in medicines containing 1 milligram or less per litre or per kilogram 154 Artemether 155 Articaine 156 Asparaginase 157 Aspirin; for injection; when combined with caffeine, paracetamol, or salicylamide 158 Astemizole 159 Atamestane 160 Atazanavir 161 Atenolol 162 Atomoxetine 163 Atorvastatin 164 Atosiban 165 Atovaquone 166 Atracurium 167 Atropa belladonna; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less of total solanaceous alkaloids per litre or per kilogram 168 Atropine; except when specified elsewhere in this schedule; except when used as an antidote in a device designed for self-injection; except in medicines containing 300 micrograms or less per litre or per kilogram 169 Atropine methonitrate 170 Auranofin 171 Aurothiomalate sodium 172 Aviptadil 173 Azacitidine 174 Azacyclonol 175 Azapropazone 176 Azaribine 177 Azatadine; except when specified elsewhere in this schedule 178 Azathioprine 179 Azelaic acid; except for dermal use 180 Azelastine; except when specified elsewhere in this schedule 181 Azithromycin 182 Azlocillin 183 Aztreonam 184 Bacampicillin 185 Bacitracin 186 Baclofen 187 Balsalazide 188 Bambuterol 189 Bamethan 190 Bamipine 191 Barbital 192 Barbiturates 193 Basiliximab 194 Bazedoxifene 195 Becaplermin 196 Beclamide 197 Beclomethasone; except when specified elsewhere in this schedule 198 Bemegride 199 Benactyzine 200 Benazepril 201 Bendrofluazide 202 Benethamine penicillin 203 Benorylate 204 Benoxaprofen 205 Benperidol 206 Benserazide 207 Benzathine penicillin 208 Benzatropine 209 Benzhexol 210 Benzilonium 211 Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit 212 Benzodiazepines 213 Benzoyl metronidazole 214 Benzoyl peroxide; except for external use in medicines containing 10% or less 234 Bismuth; except for external use in medicines containing 3% or less 235 Bisoprolol 236 Bithionol; at all strengths 237 Bivalirudin 238 Bleomycin 239 Bolandiol 240 Bolasterone 241 Bolazine 242 Boldenone 243 Bolenol 244 Bolmantalate 245 Boron including borax and boric acid; except for internal use in medicines containing 6 milligrams or less per recommended daily dose; except in dermal medicines for use other than paediatric use containing 0.35% or less; except when present as an excipient 246 Bortezomib 247 Bosentan 248 Botulinum toxins 249 Bretylium 250 Brimonidine 251 Brinzolamide 252 Bromazepam 253 Bromocriptine 254 Bromoform 255 Brompheniramine; except when specified elsewhere in this schedule 256 Bromvaletone 257 Brotizolam 258 Brugmansia spp. 259 Buclizine; except for oral use 260 Budesonide; except when specified elsewhere in this schedule 261 Bufexamac; except in suppositories or for dermal use in medicines containing 5% or less 262 Bumetanide 263 Buniodyl sodium; at all strengths 264 Buphenine 265 Bupivacaine 266 Buprenorphine 267 Bupropion 268 Buserelin 269 Buspirone 270 Busulphan 271 Butacaine 272 Butobarbital 273 Butoconazole; except for vaginal use 274 Butorphanol 275 Butyl aminobenzoate; except for dermal use in medicines containing 2% or less 276 Butyl nitrite 277 Butylchloral hydrate 278 Cabergoline 279 Cacalia spp.; at all strengths 280 Cadmium 281 Calcipotriol; except in medicines containing not more than 50 micrograms per gram or per millilitre and when sold in a pack of not more than 30 grams or 30 millilitres by a pharmacist to an adult with mild to moderate psoriasis previously diagnosed by a doctor 282 Calcitonin 283 Calcitriol 284 Calcium carbimide 285 Calcium polystyrene sulphonate 286 Calotropis gigantea 287 Calotropis procera 288 Calusterone 289 Camazepam 290 Camphorated oil 291 Camphotamide 292 Canakinumab 293 Candesartan 294 Candicidin 295 Cannabidiol 296 Capecitabine 297 Capreomycin 298 Captodiame 299 Captopril 300 Capuride 301 Caramiphen 302 Carbachol 303 Carbamazepine 304 Carbaryl; except for external use in medicines containing 2% or less 305 Carbazochrome 306 Carbenicillin 307 Carbenoxolone; for internal use 308 Carbetocin 309 Carbidopa 310 Carbimazole 311 Carbocromen 312 Carboplatin 313 Carboprost 314 Carbromal 315 Carbutamide 316 Carbuterol 317 Carindacillin 318 Carisoprodol 319 Carmustine 320 Carprofen 321 Carvedilol 322 Caspofungin 323 Cefacetrile 324 Cefaclor 325 Cefaloridine 326 Cefamandole 327 Cefapirin 328 Cefazolin 329 Cefepime 330 Cefetamet 331 Cefixime 332 Cefodizime 333 Cefonicid 334 Cefoperazone 335 Cefotaxime 336 Cefotetan 337 Cefotiam 338 Cefoxitin 339 Cefpirome 340 Cefpodoxime 341 Cefsulodin 342 Ceftazidime 343 Ceftibuten 344 Ceftriaxone 345 Cefuroxime 346 Celecoxib 347 Celiprolol 348 Cephaelis acuminata; except in medicines containing less than 0.2% of emetine 349 Cephaelis ipecacuanha; except in medicines containing less than 0.2% of emetine 350 Cephalexin 351 Cephalothin 352 Cephradine 353 Cerivastatin 354 Certolizumab pegol 355 Ceruletide 356 Cetirizine; except for oral use 357 Cetrorelix 358 Cetuximab 359 Chenodeoxycholic acid 360 Chloral hydrate; except for dermal use in medicines containing 2% or less 361 Chloralformamide 362 Chloralose 363 Chlorambucil 364 Chloramphenicol; except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when specified elsewhere in this schedule 365 Chlorandrostenolone 366 Chlorazanil 367 Chlorcyclizine 368 Chlordiazepoxide 369 Chlormerodrin 370 Chlormethiazole 371 Chlormezanone 372 Chloroform; for anaesthesia; except when specified elsewhere in this schedule 373 Chloroquine 374 Chlorothiazide 375 Chlorotrianisene 376 Chloroxydienone 377 Chloroxymesterone 378 Chlorpheniramine; except when specified elsewhere in this schedule 379 Chlorphentermine 380 Chlorpromazine 381 Chlorpropamide 382 Chlorprothixene 383 Chlorquinaldol 384 Chlortetracycline 385 Chlorthalidone 386 Chlorzoxazone 387 Cholera vaccine 388 Choline salicylate; except in medicines containing 10% or less and in pack sizes of 15 grams or less 389 Chorionic gonadotrophin; except in pregnancy test kits 390 Chymopapain 391 Ciclacillin 392 Ciclesonide 393 Ciclopirox; except for external use 394 Cidofovir 395 Cilastatin 396 Cilazapril 397 Cilostazol 398 Cimetidine; except when specified elsewhere in this schedule 399 Cinacalcet 400 Cinchocaine; for injection; for ophthalmic use; for external use in medicines containing more than 0.5% 454 Collagen; in injections or implants for tissue augmentation or cosmetic use 455 Conium maculatum; at all strengths 456 Convallaria keiski 457 Convallaria majales 458 Corifollitropin alfa 459 Coronilla spp. 460 Corticosterone 461 Corticotrophin 462 Cortisone and other steroidal hormones of the adrenal cortex; except when specified elsewhere in this schedule; except adrenal extract for dermal use in medicines containing 0.02% or less of ketosteroids 463 Cotarnine; at all strengths 464 Co-trimoxazole 465 Coumarin 466 Crotalaria spp.; at all strengths 467 Croton tiglium; except in medicines containing 1 milligram or less per litre or per kilogram 468 Crystal violet 469 Curare 470 Cyclandelate 471 Cyclizine; except for oral use 472 Cyclobenzaprine 473 Cyclofenil 474 Cycloheximide 475 Cyclopenthiazide 476 Cyclopentolate; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 477 Cyclophosphamide 478 Cyclopropane 479 Cycloserine 480 Cyclosporin 481 Cyclothiazide 482 Cycrimine 483 Cymarin 484 Cynoglossum spp.; at all strengths 485 Cyproheptadine; except for oral use 486 Cyproterone 487 Cysteamine 488 Cytarabine 489 Dabigatran 490 Dacarbazine 491 Daclizumab 492 Dactinomycin 493 Dalfopristin 494 Dalteparin 495 Danaparoid 496 Danazol 497 Danthron 498 Dantrolene 499 Dapoxetine 500 Dapsone 501 Daptomycin 502 Darbepoetin 503 Darifenacin 504 Darunavir 505 Dasatinib 506 Datura spp.; except for oral use when specified elsewhere in this schedule; except datura stramonium or datura tatula for smoking or burning 507 Daunorubicin 508 Deanol 509 Debrisoquine 510 Decamethonium 511 Deferasirox 512 Deferiprone 513 Deflazacort 514 Dehydrochloromethyltestosterone 515 Dehydrocorticosterone 516 Delavirdine 517 Delorazepam 518 Demecarium 519 Demeclocycline 520 Deoxycortone 521 Deoxyribonuclease; except for external use 522 Desferrioxamine 523 Desflurane 524 Desipramine 525 Desirudin 526 Deslanoside 527 Desloratadine; except for oral use 528 Deslorelin 529 Desmopressin 530 Desogestrel 531 Desonide 532 Desoximetasone 533 Desvenlafaxine 534 Dexamethasone 535 Dexamfetamine 536 Dexchlorpheniramine; except when specified elsewhere in this schedule 537 Dexfenfluramine 538 Dexmedetomidine 539 Dextromethorphan; except when specified elsewhere in this schedule 540 Dextromoramide 541 Dextropropoxyphene 542 Dextrorphan 543 Di-iodohydroxy quinoline; except for vaginal use 544 Di-isopropylamine dichloroacetate 545 Diazepam 546 Diazoxide 547 Dibenzepin 548 Dibotermin 549 Dibrompropamidine; except for ophthalmic use 550 Dichloralphenazone 551 Dichlorophen 552 Dichlorphenamide 553 Diclofenac; except when specified elsewhere in this schedule; except for external use 554 Dicloxacillin 555 Dicyclomine 556 Didanosine 557 Dienoestrol 558 Dienogest 559 Diethazine 560 Diethylcarbamazine 561 Diethylstilbestrol 562 Diflorasone 563 Diflucortolone 564 Diflunisal 565 Digitalis lanata 566 Digitalis purpurea 567 Digitoxin 568 Digoxin 569 Digoxin-specific antibody fragment 570 Dihydralazine 571 Dihydrocodeine 572 Dihydroergotoxine 573 Dihydrolone 574 Dihydrotachysterol 575 Diltiazem 576 Dimenhydrinate; except when specified elsewhere in this schedule 577 Dimercaprol 578 Dimethandrostanolone 579 Dimethazine 580 Dimethindene; except for oral use 581 Dimethothiazine 582 Dimethoxanate 583 Dimethyl sulphoxide 584 Dinitrocresols 585 Dinitronaphthols 586 Dinitrophenols 587 Dinitrothymols 588 Dinoprost 589 Dinoprostone 590 Diperodon 591 Diphemanil; except for dermal use 592 Diphenhydramine; except when specified elsewhere in this schedule 593 Diphenidol 594 Diphenoxylate; except when specified elsewhere in this schedule 595 Diphenylpyraline 596 Diphtheria toxoid 597 Diphtheria vaccine 598 Dipivefrin 599 Dipyridamole 600 Dirithromycin 601 Disopyramide 602 Distigmine 603 Disulfiram 604 Disulphamide 605 Ditiocarb 606 Dobutamine 607 Docetaxel 608 Dofetilide 609 Dolasetron 610 Domperidone 611 Donepezil 612 Dopamine 613 Dopexamine 614 Doripenem 615 Dornase 616 Dorzolamide 617 Dothiepin 618 Doxantrazole 619 Doxapram 620 Doxazosin 621 Doxepin 622 Doxorubicin 623 Doxycycline 624 Doxylamine; except when specified elsewhere in this schedule 625 Droperidol 626 Drospirenone 627 Drostanolone 628 Drotrecogin 629 Duboisia leichhardtii; except when specified elsewhere in this schedule 630 Duboisia myoporides; except when specified elsewhere in this schedule 631 Dulcin; at all strengths 632 Duloxetine 633 Dutasteride 634 Dydrogesterone 635 Econazole; except when specified elsewhere in this schedule 636 Ecothiopate 637 Ectylurea 638 Edetic acid; in medicines containing more than 0.25%; except in contact lens preparations; except dicobalt edetate for the treatment of cyanide poisoning 639 Edoxudine 640 Edrophonium 641 Efalizumab 642 Efavirenz 643 Eflornithine 644 Eletriptan 645 Eltrombopag olamine 646 Emepronium 647 Emetine; in medicines containing more than 0.2% 648 Emtricitabine 649 Enalapril 650 Enestebol 651 Enflurane 652 Enfuvirtide 653 Enoxacin 654 Enoxaparin 655 Enoximone 656 Enprostil 657 Entacapone 658 Entecavir 659 Ephedrine 660 Epicillin 661 Epinastine 662 Epirubicin 663 Epitiostanol 664 Eplerenone 665 Epoetins 666 Epoprostenol 667 Eprosartan 668 Eptifibatide 669 Ergocalciferol; in medicines containing more than 25 micrograms per recommended daily dose 670 Ergometrine 671 Ergot 672 Ergotamine 673 Ergotoxine 674 Erlotinib 675 Ertapenem 676 Erysimum spp.; except in medicines containing 1 milligram or less per litre or per kilogram 677 Erythromycin 678 Erythropoietin 679 Escitalopram 680 Esmolol 681 Esomeprazole 682 Estazolam 683 Estramustine 684 Estropipate 685 Etanercept 686 Ethacrynic acid 687 Ethambutol 688 Ethamivan 689 Ethanolamine; for injection 690 Ethchlorvynol 691 Ether; for anaesthesia 692 Ethinamate 693 Ethinyloestradiol 694 Ethionamide 695 Ethisterone 696 Ethoglucid 697 Ethoheptazine 698 Ethopropazine 699 Ethosuximide 700 Ethotoin 701 Ethoxzolamide 702 Ethyl chloride; for inhalation 703 Ethyl loflazepate 704 Ethyldienolone 705 Ethylhexanediol; at all strengths 706 Ethyloestrenol 707 Ethynodiol 708 Etidocaine 709 Etidronic acid; except in medicines for external use containing 1% or less 710 Etilefrine 711 Etodolac 712 Etofenamate; except for external use 713 Etonogestrel 714 Etoposide 715 Etoricoxib 716 Etravirine 717 Etretinate 718 Everolimus 719 Exemestane 720 Exenatide 721 Ezetimibe 722 Factor VIII inhibitor bypassing fraction 723 Famciclovir; except when specified elsewhere in this schedule 724 Famotidine; except when specified elsewhere in this schedule 725 Fampridine 726 Farfugium japonicum; at all strengths 727 Felbinac; except for external use 728 Felodipine 729 Felypressin; except when combined with a local anaesthetic and used in practice by a dental therapist registered with the Dental Council 730 Fenbufen 731 Fenclofenac 732 Fenfluramine 733 Fenofibrate 734 Fenoldopam 735 Fenoprofen 736 Fenoterol 737 Fenpipramide 738 Fenpiprane 739 Fentanyl 740 Fexofenadine; except for oral use 741 Fibrin 742 Fibrinolysin; except for external use 743 Filgrastim 744 Finasteride 745 Flecainide 746 Fleroxacin 747 Floctafenine 748 Fluanisone 749 Fluclorolone 750 Flucloxacillin 751 Fluconazole; except when specified elsewhere in this schedule 752 Flucytosine 753 Fludarabine 754 Fludiazepam 755 Fludrocortisone 756 Flufenamic acid 757 Flumazenil 758 Flumethasone 759 Flumethiazide 760 Flunisolide 761 Flunitrazepam 762 Fluocinolone 763 Fluocinonide 764 Fluocortin 765 Fluocortolone 766 Fluorescein; for injection 767 Fluorides; for internal use in medicines containing more than 0.5 milligrams per dose unit except in medicines containing 15 milligrams or less per litre or per kilogram; except in parenteral nutrition replacement preparations; for external use in medicines containing more than 5.5 grams per litre or per kilogram except when supplied to a dental professional registered with the Dental Council 785 Follicle-stimulating hormone; except in medicines containing 100 micrograms or less per litre or per kilogram 786 Follitropin 787 Fomivirsen 788 Fondaparinux 789 Formebolone 790 Formestane 791 Formoterol 792 Fosamprenavir 793 Fosaprepitant 794 Foscarnet 795 Fosfestrol 796 Fosinopril 797 Fosphenytoin 798 Fotemustine 799 Framycetin 800 Fulvestrant 801 Furaltadone 802 Furazabol 803 Furazolidone 804 Furosemide 805 Fusidic acid 806 Gabapentin 807 Galantamine 808 Galanthus spp. 809 Gallamine 810 Galsulfase 811 Ganciclovir 812 Ganirelix 813 Gatifloxacin 814 Gefitinib 815 Gemcitabine 816 Gemeprost 817 Gemfibrozil 818 Gemifloxacin 819 Gemtuzumab ozogamicin 820 Gentamicin 821 Gestodene 822 Gestonorone 823 Gestrinone 824 Gitalin 825 Glatiramer acetate 826 Glibenclamide 827 Glibornuride 828 Gliclazide 829 Glimepiride 830 Glipizide 831 Glisoxepide 832 Glutathione; for injection 833 Glyceryl trinitrate; for injection; for transdermal use; except in medicines containing 100 micrograms or less per litre or per kilogram 834 Glycopyrronium; for injection 835 Glymidine 836 Golimumab 837 Gonadorelin 838 Gonadotrophic hormones; except when specified elsewhere in this schedule 839 Goserelin 840 Gramicidin 841 Granisetron 842 Grepafloxacin 843 Griseofulvin 844 Guaiphenesin; for oral use in medicines containing more than 2% or 200 milligrams per dose form except when specified elsewhere in this schedule; except for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams sold in a pack containing not more than 5 days' supply approved by the Minister or the Director-General for distribution as a general sale medicine 845 Guanabenz 846 Guanethidine 847 Guanidine 848 Hachimycin 849 Haematin 850 Haemophilus influenzae vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds 851 Halazepam 852 Halcinonide 853 Halofantrine 854 Halofenate 855 Haloperidol; except in medicines containing 1 milligram or less per litre or per kilogram 856 Halothane 857 Haloxazolam 858 Halquinol; for internal use 859 Heliotropium spp.; at all strengths 860 Hemerocallis 861 Heparins; for internal use; except when present as an excipient 862 Hepatitis A vaccine 863 Hepatitis B vaccine 864 Hetacillin 865 Hexachlorophane; in medicines containing more than 3% 866 Hexamethonium 867 Hexetidine; for internal use 868 Hexobendine 869 Hexocyclium 870 Hexoprenaline 871 Histamine; in medicines containing more than 0.5% 872 Homatropine 873 Human chorionic gonadotrophin; except in pregnancy test kits 874 Human papillomavirus vaccine 875 Human protein C 876 Hyaluronic acid; in injections or implants for tissue augmentation or cosmetic use 877 Hydralazine 878 Hydrargaphen 879 Hydrochlorothiazide 880 Hydrocortisone; except when specified elsewhere in this schedule 881 Hydrocyanic acid; except when specified elsewhere in this schedule; except in medicines containing 1 microgram or less per litre or per kilogram 882 Hydroflumethiazide 883 Hydromorphone 884 Hydroquinone; except in medicines for external use containing 2% or less 885 Hydroxychloroquine 886 Hydroxyephedrine 887 Hydroxyphenamate 888 Hydroxyprogesterone 889 Hydroxystenozol 890 Hydroxyurea 891 Hydroxyzine 892 Hylan polymer; in injections or implants for tissue augmentation or cosmetic use 893 Hyoscine; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less per litre or per kilogram 894 Hyoscine butylbromide; except when specified elsewhere in this schedule 895 Hyoscyamine; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less per litre or per kilogram 896 Hyoscyamus niger; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less of total solanaceous alkaloids per litre or per kilogram 947 Isopropamide; except for dermal use in preparations containing 2% or less 948 Isosorbide dinitrate 949 Isosorbide mononitrate 950 Isotretinoin 951 Isoxicam 952 Isoxsuprine 953 Isradipine 954 Itraconazole 955 Ivabradine 956 Ivermectin 957 Ixabepilone 958 Japanese encephalitis vaccine 959 Juniperus sabina; at all strengths 960 Kanamycin 961 Ketamine 962 Ketanserin 963 Ketazolam 964 Ketoconazole; except for dermal use 965 Ketoprofen; except when specified elsewhere in this schedule; except for dermal use 966 Ketorolac 967 Ketotifen; except for ophthalmic use in medicines containing 0.025% or less 968 Khellin 969 Labetalol 970 Lacidipine 971 Lacosamide 972 Lamivudine 973 Lamotrigine 974 Lanatosides 975 Lanreotide 976 Lansoprazole; except when specified elsewhere in this schedule 977 Lanthanum 978 Lapatinib 979 Laronidase-rch 980 Laropiprant 981 Latamoxef 982 Latanoprost 983 Laudexium 984 Lauromacrogols; for injection 985 Lead 986 Lefetamine 987 Leflunomide 988 Lenalidomide 989 Lenograstim 990 Lepirudin 991 Leptazol 992 Lercanidipine 993 Letrozole 994 Leucovorin; for injection 995 Leuprorelin 996 Levallorphan 997 Levamisole 998 Levetiracetam 999 Levobunolol 1000 Levobupivacaine 1001 Levocabastine; except for nasal or ophthalmic use 1002 Levocetirizine; except for oral use 1003 Levodopa 1004 Levomepromazine 1005 Levonorgestrel; except when specified elsewhere in this schedule; except in medicines for use as emergency post-coital contraception when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health 1006 Levosimendan 1007 Lidoflazine 1008 Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or dental therapist registered with the Dental Council; for oral use except in throat lozenges containing 30 milligrams or less per dose form; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for external use in medicines containing more than 10% 1009 Ligularia dentata; at all strengths 1010 Lincomycin 1011 Lindane; except for external use in medicines containing 2% or less 1012 Linezolid 1013 Liothyronine 1014 Liraglutide 1015 Lisinopril 1016 Lisuride 1017 Lithium; except when specified elsewhere in this schedule; except when present as an excipient in dermal medicines containing 0.25% or less 1018 Lodoxamide; except in medicines for ophthalmic use 1019 Lofexidine 1020 Lomefloxacin 1021 Lomustine 1022 Loperamide; except when specified elsewhere in this schedule 1023 Lopinavir 1024 Loprazolam 1025 Loracarbef 1026 Loratadine; except for oral use 1027 Lorazepam 1028 Lormetazepam 1029 Losartan 1030 Loxapine 1031 Lumefantrine 1032 Lumiracoxib 1033 Luteinising hormone 1034 Lymecycline 1035 Mafenide 1036 Mannomustine 1037 Maprotiline 1038 Maraviroc 1039 Mazindol 1040 Measles vaccine 1041 Mebanazine 1042 Mebeverine 1043 Mebhydrolin 1044 Mebolazine 1045 Mebutamate 1046 Mecamylamine 1047 Mecasermin 1048 Mecillinam 1049 Meclocycline 1050 Meclofenamate 1051 Meclofenoxate 1052 Meclozine; except when specified elsewhere in this schedule 1053 Medazepam 1054 Medigoxin 1055 Medroxyprogesterone 1056 Medrysone 1057 Mefenamic acid; except when specified elsewhere in this schedule 1058 Mefloquine 1059 Mefruside 1060 Megestrol 1061 Melagatran 1062 Melatonin 1063 Melengestrol 1064 Melia azedarach; at all strengths 1065 Meloxicam 1066 Melphalan 1067 Memantine 1068 Meningococcal vaccine 1069 Menotrophin 1070 Mepacrine 1071 Mepenzolate 1072 Mephenesin 1073 Mephentermine 1074 Mepindolol 1075 Mepitiostane 1076 Mepivacaine 1077 Meprobamate 1078 Meptazinol 1079 Mepyramine; except when specified elsewhere in this schedule 1080 Mequitazine 1081 Mercaptomerin 1082 Mercaptopurine 1083 Mercury; except when specified elsewhere in this schedule; except in medicines containing 1 milligram or less per litre or per kilogram 1084 Meropenem 1085 Mersalyl 1086 Mesabolone 1087 Mesalazine 1088 Mesna 1089 Mestanolone 1090 Mesterolone 1091 Mestranol 1092 Metamfetamine 1093 Metandienone 1094 Metaraminol 1095 Metenolone 1096 Metergoline 1097 Metformin 1098 Methacholine 1099 Methacycline 1100 Methadone 1101 Methallenoestril 1102 Methandriol 1103 Methanthelinium 1104 Methazolamide 1105 Methdilazine; except for oral use 1106 Methicillin 1107 Methimazole 1108 Methisazone 1109 Methixene 1110 Methocarbamol 1111 Methohexitone 1112 Methoin 1113 Methotrexate 1114 Methoxamine; except for external use 1115 Methoxsalen 1116 Methoxyflurane 1117 Methsuximide 1118 Methyclothiazide 1119 Methyl aminolevulinate 1120 Methyl androstanolone 1121 Methyl clostebol 1122 Methyl mercury; except in medicines containing 300 micrograms or less per litre or per kilogram 1123 Methyl salicylate; for internal use except when present as an excipient in medicines containing 1.04% or less per dose form 1124 Methyl trienolone 1125 Methyldopa 1126 Methylene blue; for injection 1127 Methylergometrine 1128 Methylnaltrexone 1129 Methylpentynol 1130 Methylphenidate 1131 Methylphenobarbital 1132 Methylprednisolone 1133 Methyltestosterone 1134 Methylthiouracil 1135 Methyprylon 1136 Methysergide 1137 Metoclopramide; except when specified elsewhere in this schedule 1138 Metolazone 1139 Metoprolol 1140 Metribolone 1141 Metrifonate 1142 Metronidazole 1143 Metyrapone 1144 Mexiletine 1145 Mezlocillin 1146 Mianserin 1147 Mibefradil 1148 Mibolerone 1149 Miconazole; except when specified elsewhere in this schedule 1150 Midazolam 1151 Midodrine 1152 Mifepristone 1153 Miglitol 1154 Miglustat 1155 Milrinone 1156 Minocycline 1157 Minoxidil; except for dermal use in medicines containing 5% or less 1158 Mirtazapine 1159 Misoprostol 1160 Mitobronitol 1161 Mitomycin 1162 Mitoxantrone 1163 Mitragyna speciosa 1164 Mitragynine 1165 Mivacurium 1166 Moclobemide 1167 Modafinil 1168 Molgramostim 1169 Molindone 1170 Mometasone; except when specified elsewhere in this schedule 1171 Monobenzone 1172 Monoclonal antibodies; except in pregnancy test kits 1173 Montelukast 1174 Moperone 1175 Morazone 1176 Moricizine 1177 Morphine; except when specified elsewhere in this schedule 1178 Motrazepam 1179 Motretinide 1180 Moxifloxacin 1181 Mumps vaccine 1182 Mupirocin 1183 Muraglitazar 1184 Muromonab 1185 Mustine 1186 Mycophenolic acid 1187 Nabilone 1188 Nabumetone 1189 Nadolol 1190 Nadroparin 1191 Nafarelin 1192 Naftidrofuryl 1193 Nalbuphine 1194 Nalidixic acid 1195 Nalorphine 1196 Naloxone 1197 Naltrexone 1198 Nandrolone 1199 Naproxen; except when specified elsewhere in this schedule 1200 Naratriptan 1201 Natalizumab 1202 Natamycin 1203 Nateglinide 1204 Nebacumab 1205 Nebivolol 1206 Nedocromil 1207 Nefazodone 1208 Nefopam 1209 Nelfinavir 1210 Neomycin 1211 Neostigmine 1212 Nepafenac 1213 Nerium oleander 1214 Nesiritide 1215 Netilmicin 1216 Nevirapine 1217 Nialamide 1218 Nicardipine 1219 Nicergoline 1220 Nicofuranose 1221 Nicorandil 1222 Nicotine; for nasal use except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner; in medicines other than for smoking cessation 1223 Nicotinic acid except nicotinamide; in medicines containing more than 250 milligrams per dose form 1224 Nicoumalone 1225 Nifedipine 1226 Nifenazone 1227 Nikethamide 1228 Nilotinib 1229 Nilutamide 1230 Nimesulide 1231 Nimetazepam 1232 Nimodipine 1233 Nimorazole 1234 Niridazole 1235 Nisoldipine 1236 Nitrazepam 1237 Nitrendipine 1238 Nitric oxide 1239 Nitrofurantoin 1240 Nitrofurazone 1241 Nitrous oxide 1242 Nitroxoline 1243 Nizatidine; except when specified elsewhere in this schedule 1244 Nomifensine 1245 Noradrenaline 1246 Norandrostenolone 1247 Norbolethone 1248 Norclostebol 1249 Nordazepam 1250 Norelgestromin 1251 Norethandrolone 1252 Norethisterone 1253 Norfloxacin 1254 Norgestrel 1255 Noribogaine 1256 Normethandrone 1257 Nortriptyline 1258 Noxiptyline 1259 Nux vomica; except in medicines containing 1 milligram or less per litre or per kilogram of strychnine 1260 Nystatin; except when specified elsewhere in this schedule 1261 Octamylamine 1262 Octatropine 1263 Octreotide 1264 Octyl nitrite 1265 Oestradiol; except in medicines containing 10 micrograms or less per litre or per kilogram 1266 Oestriol 1267 Oestrogens 1268 Oestrone; except in medicines containing 1 milligram or less per litre or per kilogram 1269 Ofloxacin 1270 Olanzapine 1271 Oleandomycin 1272 Oleandrin 1273 Olmesartan 1274 Olopatadine 1275 Olsalazine 1276 Omalizumab 1277 Omeprazole; except when specified elsewhere in this schedule 1278 Ondansetron 1279 Opipramol 1280 Opium; except when specified elsewhere in this schedule 1281 Orciprenaline 1282 Orlistat; except in medicines for weight control containing 120 milligrams or less per dose form 1283 Ornidazole 1284 Ornipressin 1285 Orphenadrine 1286 Orthopterin 1287 Oseltamivir; except when sold in a pharmacy between the months of April to November inclusive by a registered pharmacist who is satisfied that the medicine is for the treatment of a consumer who is resident in New Zealand, is 12 years of age or more, and currently has the symptoms of influenza 1288 Ouabain 1289 Ovandrotone 1290 Oxabolone 1291 Oxacillin 1292 Oxaliplatin 1293 Oxandrolone 1294 Oxaprozin 1295 Oxazepam 1296 Oxazolam 1297 Oxcarbazepine 1298 Oxedrine; in medicines containing more than 30 milligrams per recommended daily dose 1299 Oxetacaine; except for internal use 1300 Oxiconazole; except when specified elsewhere in this schedule 1301 Oxitropium 1302 Oxolamine 1303 Oxolinic acid 1304 Oxpentifylline 1305 Oxprenolol 1306 Oxybuprocaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 1307 Oxybutynin 1308 Oxycodone 1309 Oxymesterone 1310 Oxymetholone 1311 Oxyphenbutazone 1312 Oxyphencyclimine 1313 Oxyphenisatin; at all strengths 1314 Oxyphenonium 1315 Oxytetracycline 1316 Oxytocin; except in medicines containing 1 microgram or less per litre or per kilogram 1429 Pneumococcal vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds 1430 Podophyllotoxin; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 1%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 1431 Podophyllum emodi; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 1432 Podophyllum peltatum; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 1433 Polidexide 1434 Poliomyelitis vaccine 1435 Polyacrylamide; in injections or implants for tissue augmentation or cosmetic use 1436 Polyestradiol 1437 Polylactic acid; in injections or implants for tissue augmentation or cosmetic use 1462 Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist registered with the Dental Council; except when specified elsewhere in this schedule 1463 Primaquine 1464 Primidone 1465 Probenecid 1466 Probucol 1467 Procainamide 1468 Procaine 1469 Procaine penicillin 1470 Procarbazine 1471 Prochlorperazine; except when specified elsewhere in this schedule; except when sold for the treatment of nausea associated with emergency contraception by pharmacists or nurses accredited to sell levonorgestrel for emergency contraception 1472 Procyclidine; except for dermal use in medicines containing 5% or less 1473 Progesterone; except in medicines containing 1 milligram or less per litre or per kilogram 1474 Progestogens 1475 Proglumide 1476 Proguanil 1477 Prolintane 1478 Promazine 1479 Promethazine; except when specified elsewhere in this schedule 1480 Promoxolane 1481 Propafenone 1482 Propamidine; except for ophthalmic use 1483 Propanidid 1484 Propantheline 1485 Propetandrol 1486 Propionibacterium acnes 1487 Propofol 1488 Propranolol; except in medicines containing 1 milligram or less per litre or per kilogram 1489 Propylthiouracil 1490 Propyphenazone 1491 Proquazone 1492 Proscillaridin 1493 Prostaglandins 1494 Protamine 1495 Prothionamide 1496 Prothipendyl 1497 Protirelin 1498 Protoveratrines 1499 Protriptyline 1500 Proxymetacaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 1501 Pseudoephedrine; except when specified elsewhere in this schedule 1502 Pulmonaria spp.; at all strengths 1503 Pyrazinamide 1504 Pyridinolcarbamate 1505 Pyridostigmine 1506 Pyridoxal; in medicines containing more than 200 milligrams per recommended daily dose 1507 Pyridoxamine; in medicines containing more than 200 milligrams per recommended daily dose 1508 Pyridoxine; in medicines containing more than 200 milligrams per recommended daily dose 1528 Ranitidine; except when specified elsewhere in this schedule; except in medicines containing 150 milligrams or less per dose unit that have received the consent of the Minister or the Director-General to their distribution as general sale medicines and that are sold in the manufacturer's original pack containing not more than 7 days' supply 1529 Rapacuronium 1530 Rasagiline 1531 Rasburicase 1532 Rauwolfia serpentina 1533 Rauwolfia vomitoria 1534 Razoxane 1535 Reboxetine 1536 Remifentanil 1537 Remoxipride 1538 Repaglinide 1539 Reserpine 1540 Reteplase 1541 Ribavirin 1542 Rifabutin 1543 Rifampicin 1544 Rifamycin 1545 Rifapentine 1546 Riluzole 1547 Rimexolone 1548 Rimiterol 1549 Rimonabant 1550 Risedronic acid 1551 Risperidone 1552 Ritodrine 1553 Ritonavir 1554 Rituximab 1555 Rivaroxaban 1556 Rivastigmine 1557 Rizatriptan; except when specified elsewhere in this schedule 1558 Rocuronium 1559 Rofecoxib 1560 Roflumilast 1561 Rolitetracycline 1562 Romiplostim 1563 Ropinirole 1564 Ropivacaine 1565 Rosiglitazone 1566 Rosoxacin 1567 Rosuvastatin 1568 Rotavirus vaccine 1569 Rotigotine 1570 Roxibolone 1571 Roxithromycin 1572 Rubella vaccine 1573 Ruboxistaurin 1574 Sabadilla; except in preparations containing 10 milligrams or less of total alkaloids of Schoenocaulon officinale per litre or per kilogram 1575 Safrole; for internal use except in medicines containing 0.1% or less 1576 Salbutamol 1577 Salcatonin 1578 Salmeterol 1579 Saquinavir 1580 Saxagliptin 1581 Schoenocaulon officinale; except in preparations containing 10 milligrams or less of total alkaloids of Schoenocaulon officinale per litre or per kilogram 1582 Scopolia carniolica 1583 Secbutabarbital 1584 Secobarbital 1585 Selegiline 1586 Selenium; except when specified elsewhere in this schedule; except for oral use in medicines containing 150 micrograms or less per recommended daily dose; except for external use in medicines containing 3.5% or less of selenium sulphide 1587 Sermorelin 1588 Sertindole 1589 Sertraline 1590 Serum, dried human 1591 Sevelamer 1592 Sevoflurane 1593 Sex hormones and all substances having sex hormone activity 1594 Sialoepoetin 1595 Sibutramine 1596 Silandrone 1597 Sildenafil and its structural analogues 1598 Silicones; for injection 1599 Silver sulfadiazine; except for external use in packs containing 50 grams or less 1600 Simvastatin 1601 Sirolimus 1602 Sisomicin 1603 Sitagliptin 1604 Sitaxentan 1605 Sodium bromide 1606 Sodium cellulose phosphate; for internal use 1607 Sodium cromoglycate; except for nasal and ophthalmic use 1608 Sodium morrhuate; for injection 1609 Sodium nitroprusside 1610 Sodium phosphate; in oral laxative preparations 1611 Sodium polystyrene sulphonate 1612 Sodium tetradecyl sulphate; for injection 1613 Solasadine 1614 Solifenacin 1615 Somatostatin 1616 Somatropin 1617 Sontoquine 1618 Sorafenib 1619 Sotalol 1620 Sparfloxacin 1621 Sparteine 1622 Spectinomycin 1623 Spiramycin 1624 Spirapril 1625 Spironolactone 1626 Stanolone 1627 Stanozolol 1628 Staphylococcus aureus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds 1629 Stavudine 1630 Stenbolone 1631 Steroid hormones 1632 Stilboestrol 1633 Stramonium; except for oral use where specified elsewhere in this schedule; except Datura stramonium or Datura tatula for smoking or burning 1634 Streptococcus beta-haemolyticus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds 1635 Streptodornase 1636 Streptokinase 1637 Streptomycin 1638 Strontium ranelate 1639 Strophanthins 1640 Strophanthus spp. 1641 Strychnos spp.; except in medicines containing 1 milligram or less per litre or per kilogram of strychnine 1642 Styramate 1643 Succimer 1644 Sufentanil 1645 Sugammadex 1646 Sulbactam 1647 Sulconazole; except for dermal use 1648 Sulfacetamide; except for ophthalmic use in medicines containing 10% or less 1649 Sulfadiazine; except silver sulfadiazine for external use in pack sizes of 50 grams or less 1650 Sulfadimethoxine 1651 Sulfadimidine 1652 Sulfadoxine 1653 Sulfafurazole 1654 Sulfaguanidine 1655 Sulfamerazine 1656 Sulfamethizole 1657 Sulfamethoxazole 1658 Sulfamethoxydiazine 1659 Sulfamethoxypyridazine 1660 Sulfametrole 1661 Sulfamonomethoxine 1662 Sulfamoxole 1663 Sulfaphenazole 1664 Sulfapyridine 1665 Sulfasalazine 1666 Sulfathiazole 1667 Sulfatroxazole 1668 Sulfinpyrazone 1669 Sulfomyxin 1670 Sulfonmethane 1671 Sulindac 1672 Sultamicillin 1673 Sulthiame 1674 Sumatriptan; except when specified elsewhere in this schedule 1675 Sunitinib 1676 Suprofen 1677 Sutilains 1678 Suxamethonium 1679 Suxethonium 1680 T cell receptor antibody 1681 Tacrine 1682 Tacrolimus 1683 Tadalafil and its structural analogues 1684 Tamoxifen 1685 Tamsulosin 1686 Tanacetum vulgare; in medicines containing more than 0.8% of oil of tansy 1687 Tapentadol 1688 Tasonermin 1689 Tazarotene 1690 Tazobactam 1691 Tegafur 1692 Tegaserod 1693 Teicoplanin 1694 Telbivudine 1695 Telithromycin 1696 Telmisartan 1697 Temazepam 1698 Temozolomide 1699 Temsirolimus 1700 Tenecteplase 1701 Teniposide 1702 Tenofovir 1703 Tenoxicam 1704 Terazosin 1705 Terbinafine; except when specified elsewhere in this schedule 1706 Terbutaline 1707 Terfenadine 1708 Teriparatide 1709 Terlipressin 1710 Terodiline 1711 Teropterin 1712 Testolactone 1713 Testosterone; except in medicines containing 1 milligram or less per litre or per kilogram 1714 Tetanus antitoxin 1715 Tetanus toxoid 1716 Tetanus vaccine 1717 Tetrabenazine 1718 Tetracosactrin 1719 Tetracycline 1720 Tetraethylammonium 1721 Tetrahydrocannabinol 1722 Tetrazepam 1723 Tetroxoprim 1724 Thalidomide 1725 Thenyldiamine 1726 Theophylline; except in liquid form for oral use in medicines containing 2% or less 1727 Thevetia peruviana 1728 Thevetin 1729 Thiambutosine 1730 Thiazosulfone 1731 Thiethylperazine 1732 Thioacetazone 1733 Thiocarlide 1734 Thioguanine 1735 Thiomesterone 1736 Thiopentone 1737 Thiopropazate 1738 Thioproperazine 1739 Thioridazine 1740 Thiotepa 1741 Thiothixene 1742 Thiouracil 1743 Thiourea; except in medicines containing 0.1% or less 1744 Thymoxamine 1745 Thyroid 1746 Thyrotrophin 1747 Thyrotrophin-releasing factor 1748 Thyroxine; except in medicines containing 10 micrograms or less per litre or per kilogram 1749 Tiagabine 1750 Tiaprofenic acid 1751 Tiaramide 1752 Tibolone 1753 Ticarcillin 1754 Ticlopidine 1755 Tiemonium 1756 Tienilic acid 1757 Tigecycline 1758 Tigloidine 1759 Tiletamine 1760 Tilidine 1761 Tiludronic acid 1762 Timolol 1763 Tinidazole 1764 Tinzaparin 1765 Tioconazole; except when specified elsewhere in this schedule 1766 Tiotropium 1767 Tipepidine 1768 Tiprinavir 1769 Tirilazad 1770 Tirofiban 1771 Tobramycin 1772 Tocainide 1773 Tocilizumab 1774 Tolazamide 1775 Tolazoline 1776 Tolbutamide 1777 Tolcapone 1778 Tolfenamic acid 1779 Tolmetin 1780 Tolonium 1781 Tolpropamine 1782 Tolrestat 1783 Tolterodine 1784 Topiramate 1785 Topotecan 1786 Torasemide 1787 Toremifene 1788 Toxoids; for injection 1789 Tramadol 1790 Trandolapril 1791 Tranexamic acid 1792 Tranylcypromine 1793 Trastuzumab 1794 Travoprost 1795 Trazodone 1796 Trenbolone 1797 Treosulphan 1798 Treprostinil 1799 Trestolone 1800 Tretamine 1801 Tretinoin 1802 Triacetyloleandomycin 1803 Triamcinolone; except when specified elsewhere in this schedule 1804 Triamterene 1805 Triaziquone 1806 Triazolam 1807 Trichlormethiazide 1808 Trichloroacetic acid; except for external use in medicines containing 12.5% or less for the treatment of warts other than anogenital warts 1809 Trichloroethylene 1810 Trichodesma africana; at all strengths 1811 Triclofos 1812 Tricyclamol 1813 Tridihexethyl 1814 Trifluoperazine 1815 Trifluperidol 1816 Triflupromazine 1817 Trimeprazine; except when specified elsewhere in this schedule 1818 Trimetaphan 1819 Trimethoprim 1820 Trimipramine 1821 Trimustine 1822 Trinitrophenol 1823 Trioxysalen 1824 Triparanol; at all strengths 1825 Triple antigen vaccine 1826 Triprolidine; except when specified elsewhere in this schedule 1827 Triptorelin 1828 Troglitazone 1829 Trometamol; for injection in medicines containing more than 3% 1830 Tropicamide; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 1879 Vitamin A; for internal use in medicines containing more than 3 milligrams of retinol equivalents per recommended daily dose except in parenteral nutrition replacement preparations; for external use in medicines containing more than 1% 1880 Vitamin D; for internal use in medicines containing more than 25 micrograms per recommended daily dose except in parenteral nutrition replacement preparations 1881 Voriconazole 1882 Warfarin 1883 Xamoterol 1884 Xanthinol nicotinate 1885 Ximelagatran 1886 Xipamide 1887 Yellow fever vaccine 1888 Yohimbine 1889 Zafirlukast 1890 Zalcitabine 1891 Zaleplon 1892 Zanamivir 1893 Zidovudine 1894 Zimeldine 1895 Zinc; for internal use in medicines containing more than 25 milligrams per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director-General to their distribution as general sale medicines and that are sold in the manufacturer's original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except in parenteral nutrition replacement preparations 1896 Ziprasidone 1897 Zoledronic acid 1898 Zolmitriptan; except when specified elsewhere in this schedule 1899 Zolpidem 1900 Zonisamide 1901 Zopiclone 1902 Zoxazolamine 1903 Zuclopenthixol Part 2 Restricted medicines 1 Adrenaline; in medicines containing 1% or less and more than 0.02% 2 Alclometasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines and that are sold in the manufacturer's original pack 3 Aminophylline; for oral use in liquid form in medicines containing 2% or less 4 Amorolfine; for external use in medicines containing more than 0.25% 5 Aspirin; in slow-release forms; in enteric coated forms containing more than 300 milligrams per dose form; except when specified elsewhere in this schedule 6 Azatadine; for oral use in adults and children over 2 years of age 7 Azelastine; in medicines for ophthalmic use containing 0.05% or less 8 Brompheniramine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule 9 Buclizine; for oral use 10 Butoconazole; for vaginal use 11 Chloramphenicol; for ophthalmic use; except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 12 Chlorbutol; in medicines containing more than 5% 13 Chlorpheniramine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule 14 Ciclopirox; for external use in medicines containing more than 2% 15 Cimetidine; in medicines that have received the consent of the Minister or the Director-General to their distribution as restricted medicines and that are sold in the manufacturer's original pack containing not more than 14 days' supply 16 Clemastine; for oral use 17 Clobetasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines and that are sold in the manufacturer's original pack 18 Clotrimazole; for vaginal use 19 Codeine; in medicines for oral use containing not more than 15 milligrams of codeine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of codeine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, for use as an analgesic and when sold in a pack of not more than 5 days' supply, approved by the Minister or the Director-General for distribution as a restricted medicine 20 Cyclizine; for oral use 21 Cyproheptadine; for oral use 22 Dexchlorpheniramine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule 23 Di-iodohydroxy quinoline; for vaginal use 24 Diclofenac; in solid dose form in medicines containing 25 milligrams or less and more than 12.5 milligrams per dose form in packs containing not more than 30 tablets or capsules 25 Dimenhydrinate; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule 26 Dimethindene; for oral use 27 Diphenhydramine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule 28 Dithranol 29 Doxylamine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule 30 Econazole; for vaginal use 31 Erythrityl tetranitrate 32 Famciclovir; in tablets containing 500 milligrams or less when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine 33 Flavoxate 34 Fluconazole; for oral use in medicines that have received the consent of the Minister or the Director-General to their distribution as restricted medicines and that are sold in the manufacturer's original pack containing 150 milligrams or less as a single dose for the treatment of vaginal candidiasis 35 Fluorides; for external use in liquid form in medicines containing 5.5 grams or less and more than 1 gram per litre or per kilogram and when sold in packs approved by the Minister or the Director-General for distribution as restricted medicines; for external use in non-liquid form in medicines containing 5.5 grams or less and more than 1 gram per litre or per kilogram, except in medicines containing 1.5 grams or less and more than 1 gram per litre or per kilogram; except when supplied to a dental professional registered with the Dental Council 36 Glucagon; except in medicines containing 100 micrograms or less per litre or per kilogram 37 Glyceryl trinitrate; for oral or sublingual use; for rectal use 38 Glycopyrronium; except for injection 39 Guaiphenesin; for oral use in modified-release form with a maximum recommended daily dose of not more than 2.4 grams sold in a pack containing more than 5 days' supply but not more than 30 days' supply approved by the Minister or the Director-General for distribution as a restricted medicine 40 Haemophilus influenzae vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds 41 Hydrocortisone and hydrocortisone acetate but no other esters of hyrocortisone; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other active ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; in rectal medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or up to 12 suppositories per pack 42 Hyoscine butylbromide; for oral use in medicines containing not more than 10 milligrams per dose form and in packs containing not more than 20 tablets or capsules 43 Ibuprofen; for oral use in tablets or capsules containing up to 400 milligrams per dose form and in packs containing not more than 50 dose units and that have received the consent of the Minister or the Director-General to their distribution as restricted medicines and that are sold in the manufacturer's original pack labelled for use by adults and children over 12 years of age 44 Inositol nicotinate 45 Isoconazole; for vaginal use 46 Ketoprofen; in solid dose form containing 25 milligrams or less per dose form in packs of not more than 30 capsules or tablets 47 Lansoprazole; in tablets or capsules containing 15 milligrams or less when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine 48 Levonorgestrel; in medicines for use as emergency post-coital contraception when in packs containing not more than 1.5 milligrams except when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health 52 Mepyramine; for oral use in medicines for adults and children over 2 years of age 53 Methdilazine; for oral use 54 Metoclopramide; when compounded with paracetamol in packs of not more than 10 tablets or capsules for the treatment of nausea associated with migraine 55 Miconazole; for the treatment of oral candidiasis; for vaginal use 56 Nicotinic acid except nicotinamide; in medicines containing 250 milligrams or less but more than 100 milligrams per dose form 57 Nicotinyl alcohol; in medicines containing more than 100 milligrams per dose form 58 Nystatin; for the treatment of oral candidiasis; for vaginal use 59 Omeprazole; in tablets or capsules containing 20 milligrams or less when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine 60 Orlistat; in medicines for weight control containing 120 milligrams or less per dose form 61 Oxiconazole; for vaginal use 62 Pantoprazole; in tablets or capsules containing 20 milligrams or less of pantoprazole when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine 63 Pheniramine; for oral use in medicines for adults and children over 2 years of age 64 Pneumococcal vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds 65 Podophyllotoxin; for external use for the treatment of warts other than anogenital warts in medicines containing 1% or less and more than 0.5%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 66 Podophyllum emodi; for external use for the treatment of warts other than anogenital warts in medicines containing 20% or less and more than 10% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 67 Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in medicines containing 20% or less and more than 10% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 68 Prochlorperazine; in packs containing not more than 10 tablets or capsules for the treatment of nausea associated with migraine 69 Promethazine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule 70 Rizatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms, when in wafers containing 5 milligrams or less per wafer and when sold in a pack containing not more than 2 wafers approved by the Minister or the Director-General for distribution as a restricted medicine 71 Salicylic acid; except in medicines for dermal use containing 40% or less 75 Staphyloccocus aureus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds 76 Stramonium; for oral use in liquid form; in solid dose form in medicines containing more than 0.3 milligrams per dose or more than 1.2 milligrams per recommended daily dose 77 Streptococcus beta-haemolyticus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds 78 Sulfacetamide; for ophthalmic use in medicines containing 10% or less 79 Sumatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms when in tablets containing 50 milligrams or less per tablet and when sold in a pack containing not more than 2 tablets that has received the consent of the Minister or the Director-General to its sale as a restricted medicine 80 Theophylline; in liquid form for oral use in medicines containing 2% or less 81 Tioconazole; for vaginal use 82 Triamcinolone; for buccal use in medicines containing 0.1% or less of triamcinolone acetonide and in pack sizes of 5 grams or less 83 Trimeprazine; for oral use in adults and children over 2 years of age; except when specified elsewhere in this schedule 84 Triprolidine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule 85 Zolmitriptan; in a pre-filled nasal spray device containing not more than 5 milligrams of zolmitriptan, for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms and when sold in a pack of not more than 2 devices approved by the Minister or the Director-General for distribution as a restricted medicine Part 3 Pharmacy-only medicines 1 8-hydroxyquinoline and its non-halogenated derivatives; in medicines containing more than 1% of such substances 2 Acetic acid and preparations containing more than 80% of acetic acid (CH 3 COOH); excluding its salts and derivatives 3 Acetylcysteine; for oral use in medicines containing more than 1 gram per recommended daily dose 4 Aciclovir; for external use for the treatment of herpes labialis except in medicines containing 5% or less and in tubes containing 10 grams or less 5 Aconitum spp.; for oral use in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids; for dermal use in concentrations of 0.02% or less and in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids 6 Aloes; for internal use; except when obtained solely from the mucilaginous gel of the leaf 7 Aloin 8 Aloxiprin 9 Amethocaine; for external use in medicines containing 10% or less and more than 2% 10 Amorolfine; for external use in medicines containing 0.25% or less except in medicines for tinea pedis only 11 Antazoline; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 12 Atropa belladonna; for external use in medicines containing 0.03% or less of the alkaloids of belladonna; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of the alkaloids of belladonna or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of the alkaloids of belladonna 13 Atropine; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose; in medicines containing atropine sulphate for the treatment of organophosphorus poisoning either in packs of not more than 20 dose units containing 0.6 milligrams or less per dose unit or in injections in packs of not more than 5 vials containing 0.6 milligrams per millilitre; except when sold as an antidote in a device designed for self-injection from outlets licensed to sell organophosphorus poisons; except in medicines containing 300 micrograms or less per litre or per kilogram 14 Azelaic acid; for dermal use 15 Azelastine; for nasal use 16 Beclomethasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 400 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine 17 Benzocaine; in preparations for topical use, other than eye drops, containing 10% or less of total anaesthetic substances except in dermal preparations containing 2% or less of total anaesthetic substances; in divided preparations containing 200 milligrams or less of total anaesthetic substances per dosage unit except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit 18 Benzoyl peroxide; for external use in medicines containing more than 5% and not more than 10% 19 Benzydamine; for external use except for dermal use 20 Bephenium 21 Bifonazole; for dermal use except in medicines for tinea pedis only or in shampoos containing 1% or less 22 Bisacodyl 23 Bromhexine 24 Brompheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing brompheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant 25 Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine 26 Carbetapentane; in medicines containing more than 0.5% 27 Carbocisteine 28 Cetirizine; for oral use 29 Chlophedianol 30 Chlorbutol; in medicines containing 5% or less and more than 0.5% 31 Chloroform; in medicines other than for anaesthesia containing more than 0.5% 32 Chlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing chlorpheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant 33 Ciclopirox; for external use in medicines containing 2% or less except in medicines for tinea pedis only 34 Cinchocaine; for external use in medicines containing 0.5% or less 35 Cinnamedrine 36 Clotrimazole; for external use except in medicines for tinea pedis only 37 Cocaine; in medicines for oral use, containing not more than 0.1% of cocaine when combined with 1 or more active ingredients, in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health and when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 38 Codeine; in medicines for oral use, containing not more than 15 milligrams of codeine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of codeine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, for the treatment of the symptoms of cough and cold and when sold in a pack of not more than 6 days' supply, approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 39 Colocynth 40 Creosote; in medicines containing more than 10% 41 Cresols; in medicines containing more than 3% 42 Datura spp.; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids 43 Delphinium staphisagria; in medicines containing more than 0.2% 44 Desloratadine; for oral use 45 Dexchlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing dexchlorpheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant 46 Dextromethorphan; in liquid form containing more than 0.25% or in solid dose form containing more than 15 milligrams per dose form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of the symptoms of cough and cold in children aged 6 -- 12 years 47 Dibrompropamidine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 48 Diclofenac; in solid dose form in medicines containing 12.5 milligrams or less per dose form in packs containing not more than 30 tablets or capsules and with a recommended daily dose of not more than 75 milligrams 49 Diphenoxylate; in liquid form containing in each millilitre not more than 0.5 milligrams of diphenoxylate calculated as base and not less than 5 micrograms of Atropine sulphate; in solid dose form containing not more than 2.5 milligrams of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate 50 Dimenhydrinate; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults or children over 2 years of age except when sold at a transport terminal or aboard a ship or aircraft 51 Diphenhydramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing diphenhydramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a transport terminal or aboard a ship or aircraft 52 Doxylamine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing doxylamine or when at least 1 of the other active ingredients is a sympathomimetic decongestant 53 Duboisia leichhardtii; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids 54 Duboisia myoporides; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids 55 Econazole; for dermal use except in medicines for tinea pedis only 56 Etafedrine 57 Ether; in medicines containing more than 10% 58 Etofenamate; for external use 59 Famotidine; in medicines that have received the consent of the Minister or the Director-General to their distribution as pharmacy-only medicines and that are sold in the manufacturer's original pack containing not more than 14 days' supply 60 Felbinac; for external use 61 Fexofenadine; for oral use except when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride when sold in a pack approved by the Minister or the Director-General for distribution as a general sales medicine 62 Fluorides; for internal use in medicines containing 0.5 milligrams or less per dose unit; except in parenteral nutrition replacement preparations; for external use in liquid form in medicines containing 1 gram or less per litre or per kilogram and when sold in packs approved by the Minister or the Director-General for distribution as pharmacy-only medicines except in medicines containing 220 milligrams or less per litre or per kilogram and in packs containing not more than 120 milligrams of total fluoride; except when supplied to any dental professional registered with the Dental Council; except in medicines containing 15 milligrams or less per litre or per kilogram 64 Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 200 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine 65 Folic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose 66 Folinic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose 67 Formaldehyde; in medicines containing more than 5% 68 Gelsemium sempervirens; except in medicines containing 1 milligram or less per litre or per kilogram 69 Glutaraldehyde 70 Hexachlorophane; in medicines containing 3% or less but more than 0.75% 71 Hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; for dermal use in medicines containing 0.5% or less by weight of hydrocortisone base with no other active ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; in rectal medicines containing 0.5% or less by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or 12 suppositories or fewer per pack 72 Hydrocyanic acid; for oral use in packs containing 5 milligrams or less and more than 0.5 milligrams; except in medicines containing 1 microgram or less per litre or per kilogram 73 Hydroquinone; for external use in medicines containing 2% or less except in hair preparations containing 1% or less 74 Hyoscine; for transdermal use in medicines containing 2 milligrams or less of total solanaceous alkaloids per dose unit; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids 75 Hyoscyamine; for external use in medicines containing 0.03% or less of total solanaceous alkaloids; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids 76 Hyoscyamus niger; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose except in packs containing 30 micrograms or less of total solanaceous alkaloids 77 Ibuprofen; for oral use in liquid form in packs containing not more than 4 grams in medicines that have received the consent of the Minister or the Director-General to their distribution as pharmacy-only medicines and that are sold in the manufacturer's original pack; for oral use in solid dose form containing not more than 200 milligrams per dose form and with a recommended daily dose of not more than 1.2 grams and in packs containing not more than 100 dose units and when in medicines that have received the consent of the Minister or the Director-General to their distribution as pharmacy-only medicines and that are sold in the manufacturer's original pack; except in packs containing 200 milligrams or less per oral solid dose form and not more than 25 dose units per pack in medicines that have received the consent of the Minister or the Director-General to their distribution as general sale medicines and that are sold in the manufacturer's original pack 78 Indanazoline 79 Indomethacin; for external use in medicines containing 1% or less; except in medicines containing 1 milligram or less per litre or per kilogram 80 Iodine; for external use in medicines containing more than 2.5%; for internal use in medicines containing 300 micrograms or more per recommended daily dose 81 Ipecacuanha; in medicines containing 0.2% or less of emetine and 40 micrograms or more of ipecacuanha alkaloids per recommended dose for the treatment of the symptoms of cough and cold in children aged 6 -- 12 years 82 Ipomoea 83 Ipratropium; for nasal use 84 Iron; for oral use either in medicines containing more than 24 milligrams per recommended daily dose or in medicines containing more than 5 milligrams per dose unit and more than 750 milligrams of iron per pack; except in parenteral nutrition replacement preparations 85 Isoconazole; for dermal use 86 Isopropamide; for dermal use in preparations containing 2% or less 87 Jalap resin 88 Ketoconazole; for dermal use except in medicines for tinea pedis only or in medicines for treatment of the scalp containing 1% or less 89 Ketotifen; for ophthalmic use in medicines containing 0.025% or less except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 90 Leucovorin; in medicines containing more than 500 micrograms per recommended daily dose 91 Levocabastine; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 92 Levocetirizine; for oral use 93 Lignocaine; for urethral use; for external use in medicines containing 10% or less and more than 2% 94 Lindane; for external use in medicines containing 2% or less 95 Lithium; for dermal use in medicines containing 1% or less but more than 0.01%; except when present as an excipient in dermal medicines containing 0.25% or less 96 Lobelia inflata; except in medicines for smoking or burning 97 Lobeline; except when in medicines for smoking or burning 98 Lodoxamide; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 99 Loperamide; in packs containing not more than 20 tablets or capsules; except in divided solid dosage forms for oral use containing 2 milligrams or less of loperamide per dosage form when sold in a pack containing not more than 8 dosage forms approved by the Minister or the Director-General for distribution as a general sales medicine for the symptomatic treatment of acute non-specific diarrhoea 100 Loratadine; for oral use 101 Mebendazole 102 Meclozine; in a sealed container of not more than 12 tablets or capsules for the prevention or treatment of travel sickness except when sold at a transport terminal or aboard a ship or aircraft 103 Mefenamic acid; in solid dose form in packs containing not more than 30 tablets or capsules for the treatment of dysmenorrhoea 104 Mepyramine; for dermal use 105 Mercuric oxide; for ophthalmic use 106 Mercury; for external use in medicines containing 0.5% or less 107 Methoxamine; for external use in medicines containing more than 1% 108 Methoxyphenamine 109 Methylephedrine 110 Miconazole; for external use except in medicines for tinea pedis only 111 Minoxidil; for dermal use in medicines containing 5% or less 112 Mometasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation and when the maximum recommended daily dose is no greater than 200 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine 113 Morphine; in medicines for oral use containing not more than 0.2% of morphine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 114 Naphazoline; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 115 Naproxen; in solid dose form containing 250 milligrams or less per dose form in packs of not more than 30 tablets or capsules 116 Niclosamide 117 Nicotine; for inhalation except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner, nurse, pharmacist, or psychologist 118 Nizatidine; in medicines that have received the consent of the Minister or the Director-General to their distribution as pharmacy-only medicines and that are sold in the manufacturer's original pack containing not more than 14 days' supply 119 Noscapine 120 Nystatin; for dermal use 121 Omeprazole; in divided solid dosage forms for oral use containing 20 milligrams or less, with a maximum daily dose of 20 milligrams in a pack size of up to 14 dosage units, for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 122 Opium; in medicines for oral use containing not more than 0.2% of morphine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 123 Oxetacaine; for internal use 124 Oxiconazole; for dermal use except in medicines for tinea pedis only 125 Oxymetazoline; except for nasal use when sold at an airport; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 126 Papaverine; except for injection 127 Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams; in slow-release forms containing 665 milligrams or less and more than 500 milligrams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack 128 Paraformaldehyde; in medicines containing more than 5% 129 Penciclovir; for external use for the treatment of herpes labialis 130 Phedrazine 131 Phenazone; for external use 132 Pheniramine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing pheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant 133 Phenol; in medicines other than for injection containing more than 3% 134 Phenylephrine; for nasal use in medicines containing more than 1%; for ophthalmic use in medicines containing 5% or less and more than 1%; for oral use in medicines containing more than 50 milligrams per recommended daily dose or in packs containing more than 250 milligrams of phenylephrine per pack; in medicines for the treatment of the symptoms of cough and cold in children aged 6 -- 12 years 135 Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 136 Piperazine 137 Podophyllotoxin; for external use for the treatment of warts other than anogenital warts in medicines containing 0.5% or less; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 138 Podophyllum emodi; for external use for the treatment of warts other than anogenital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 139 Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 140 Potassium; for internal use: in slow-release or enteric coated forms; in medicines containing more than 100 milligrams per recommended dose except in medicines for oral rehydration therapy, parenteral nutrition replacement, or dialysis; except in glucosamine sulphate complexed products containing 600 milligrams or less of potassium chloride per recommended dose 141 Potassium chlorate; except in medicines containing 10% or less 142 Prilocaine; for dermal use in medicines containing 10% or less of local anaesthetic substances 143 Procyclidine; for dermal use in medicines containing 5% or less 144 Promethazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing promethazine or when at least 1 of the other active ingredients is a sympathomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a transport terminal or aboard a ship or aircraft 145 Propamidine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 146 Pseudoephedrine; in medicines for oral use containing not more than 60 milligrams of pseudoephedrine per solid dosage unit or per dose of liquid, and containing either a single ingredient or when combined with 1 or more active ingredients, when sold in a pack containing not more than 1.8 grams of pseudoephedrine, approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 147 Pyrantel 148 Pyrethrins; in medicines containing more than 10% 149 Pyrithione zinc; except in medicines for treatment of the scalp containing 2% or less 150 Ranitidine; in medicines that have received the consent of the Minister or the Director-General to their distribution as pharmacy-only medicines and that are sold in the manufacturer's original pack containing not more than 14 days' supply; except in medicines containing 150 milligrams or less per dose unit that have received the consent of the Minister or the Director-General to their distribution as general sale medicines and that are sold in the manufacturer's original pack containing not more than 7 days' supply 151 Salicylamide 152 Selenium; for oral use in medicines containing 300 micrograms or less and more than 150 micrograms per recommended daily dose; for external use except in medicines containing 3.5% or less of selenium sulphide 153 Sennosides 154 Silver; except in oral solutions containing 0.3% or less or other medicines containing 1% or less 155 Silver sulfadiazine; for external use in pack sizes of 50 grams or less 156 Sodium cromoglycate; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 157 Sodium nitrite; except for use as an excipient 158 Sodium picosulphate; in oral laxative preparations 159 Squill; in medicines containing more than 1% 160 Stramonium; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids 161 Sulconazole; for dermal use 162 Sulfadiazine, silver; for external use in pack sizes of 50 grams or less 163 Terbinafine; for dermal use except in medicines for tinea pedis only 164 Tetrachloroethylene 165 Tetrahydrozoline; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 166 Thiabendazole 167 Tioconazole; for dermal use except in medicines for tinea pedis only 168 Tramazoline 169 Triamcinolone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age and when in aqueous nasal sprays delivering up to 55 micrograms per actuation when the maximum recommended daily dose is no greater than 220 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine 170 Trimeprazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing trimeprazine or when at least 1 of the other therapeutically active ingredients is a sympathomimetic decongestant 171 Triprolidine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing triprolidine or when at least 1 of the other active ingredients is a sympathomimetic decongestant 172 Tuaminoheptane 173 Tymazoline 174 Xylenols; in medicines containing more than 3% 175 Xylometazoline; except for nasal use when sold at an airport; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 176 Zinc chloride; for dermal use in medicines containing more than 5% Schedule 2 [ Before completing this form you should make yourself familiar with the provisions of the Medicines Act 1981 and the Medicines Regulations 1984, especially those parts that deal with licences. This form may be used to apply for licences to manufacture, pack, sell, or hawk medicines. It is divided into 7 parts. Every applicant must complete either Part 1 or Part 2, and must also complete at least one of Parts 3, 4, 5, 6, and 7. Every application must be accompanied by the prescribed fee for each licence applied for (viz, regulation 61 , Medicines Regulations 1984).] The form must be completed in type, or in block capitals. Part 1 [ To be completed where the applicant is an individual applying for a licence on his own behalf .] Name of applicant: [ surname ] [ first names ] I am a New Zealand resident: Yes / No Date of birth: [ day / month / year ] Address ( home ): Name of business: Street address of business premises: Postal address: General nature of business: Position of applicant (for example, " owner " , " manager " etc): Have you previously held a licence to manufacture, pack, sell, or hawk medicines? Yes / No If yes give details: Have you ever been declined, or had revoked, a licence to manufacture, pack, sell, or hawk medicines? Yes / No If yes give details: Part 2 [ To be completed where the applicant is an officer of a body corporate applying for a licence on behalf of the body corporate .] Have any of the above nominees ever been declined, or had revoked, a licence to manufacture, pack, sell, or hawk medicines? Yes/No If yes give details: Have any of the above nominees ever been a licensee or responsible person under the Restricted Drugs Act 1960 or the Medicines Act 1981 ? Yes / No If yes give details: Part 3 Application to manufacture medicines I hereby make application for a licence to manufacture the medicines listed below (attach extra list if insufficient space provided here). Indicate (by reference to one of the following paragraphs) which of the following classes the medicines come within: (a) antibiotics, or preparations of antibiotics: (b) vaccines and sera: (c) sterile preparations: (d) hormones and steroid preparations: (e) preparations, other than vitamins, having a dose of 5 milligrams or less per unit dose: (f) antineoplastic agents and immunosuppressant agents other than steroid preparations: (g) other medicines not included in paragraphs (a) to (f), above. Appropriate designation Trade name of medicine Class Premises where manufacture (including packing and labelling) of the medicines will be carried out: I enclose the fee of: Signature of applicant (or Common Seal where applicant is a body corporate): Date: Part 4 Application to pack medicines I hereby make application for a licence to pack the medicines listed below (attach extra list if insufficient space provided here). Indicate in the third column whether the medicine is a prescription medicine, restricted medicine, or pharmacy-only medicine. Appropriate designation Trade name of medicine Class Premises where packing and labelling will be carried out: I enclose the fee of: Signature of applicant (or Common Seal where applicant is a body corporate): Date: Part 5 Application to sell medicines by wholesale I hereby make application to sell by wholesale the following medicines (attach extra list if insufficient space provided here): Premises from where medicines are to be sold: I enclose the fee of: Signature of applicant (or Common Seal where applicant is a body corporate): Date: Part 6 Application to sell medicines by retail I hereby make application to sell by retail the following medicines (attach extra list if insufficient space provided here): Premises from where medicines are to be sold: I declare the above premises are more than 10 kilometres by road from the nearest pharmacy. The reasons for this application are: I enclose the fee of: Signature of applicant (or Common Seal where applicant is a body corporate): Date: Part 7 Application to hawk medicines I hereby make application for a licence to hawk medicines. Premises where stock of medicines will be kept: Place where records of sale of medicines will be kept: Geographical area in which it is proposed to hawk medicines: Persons or classes of persons to whom it is proposed to hawk medicines: Name and maximum quantity of medicines intended to be transported when hawking: I enclose the fee of: Signature of applicant (or Common Seal where applicant is a body corporate): Form 1A Application for licence to operate pharmacy made (by employee or agent) on behalf of company Important information Before filling out this application please note the following important information: this form may be used by an employee or agent who is making an application on behalf of a company: you must make yourself familiar with the provisions of the Medicines Act 1981 and the Medicines Regulations 1984, in particular those provisions relating to licensing and operating pharmacies: the following must accompany this application: the prescribed fee: a completed statutory declaration: it is an offence to make a false statutory declaration: the licensing authority may require you to supply additional information at a later date ( see section 55B of the Medicines Act 1981). If you do not supply that information within 30 days of the request, this application will lapse. Please complete the following: Applicant and company I, [ full name of employee or agent of company ], [ position in company ], make this application for a licence to operate a pharmacy on behalf of [ name of company ], which --  (a) was incorporated in New Zealand on [ date of incorporation ]; and (b) has the following board members: [ full names of all board members ]. The address of the company is [ address ]. The following persons are nominated to be responsible persons for the purposes of the licence under the Medicines Act 1981 : [ full names, dates of birth, and positions held ]. Street address and description of pharmacy The street address of the pharmacy to which this application relates is [ street address ]. The pharmacy will comprise the following part or parts of that street address: [ specify the part or parts of the street address that are to be a pharmacy or attach a line drawing showing the part or parts ]. Interests held in pharmacy Note : Before filling out this part of the form please read section 5A of the Medicines Act 1981, which sets out the meaning of holding an interest in a pharmacy . The following person(s) or company ( or companies) hold an interest in the pharmacy (as defined in section 5A of the Medicines Act 1981) to which this application relates: [ name(s) of person(s) or company (or companies), their address(es), and the particulars of the interest held (or " none " if applicable) ]. The following person(s) who hold an interest in the pharmacy to which this applicaton relates is a ( or are) practioner(s) ( or registered midwife (midwives)) ( or designated prescriber(s)): [ name of the interest holder(s) and his or her relevant position (or " none " if applicable) ]. Eligibility to hold licence *The share capital of the company is more than 50% owned by [ full name of pharmacist ] who is a pharmacist+ ( or [ full names of pharmacists ] who are pharmacists) and effective control of the company is vested in the above-named pharmacist ( or pharmacists). includes an administrator of the estate of a deceased pharmacist, and an assignee within the meaning of the Insolvency Act 1967 of the estate of a pharmacist, until --  (i) the expiry of the period of 1 year after the date of the death of the deceased pharmacist, or the date on which the pharmacist was adjudicated bankrupt; or or (ii) subject to any conditions that the licensing authority proposes, the extended period or periods permitted by the licensing authority. or *The pharmacy to which this application relates is in a hospital owned or operated by the company. [ Specify details .] or *[ Specify other ground in section 55D(2) of the Medicines Act 1981 that makes the company eligible to hold a licence. ] *Delete if inapplicable. Practices and procedures for pharmacists working in pharmacy The following practices and procedures will be in place to ensure that any pharmacist* who is employed or engaged in duties in the pharmacy to which this application relates is not requested or required to act in a way that is inconsistent with the applicable professional or ethical standards of the pharmacy practice: [ specify relevant practices and procedures ]. Form 1B Application for licence to operate pharmacy made by person who is individual ( or employee or agent of body corporate that is not company) Important information Before filling out this application please note the following important information: this form may be used by --  an individual who is applying for a licence to operate a pharmacy; or an employee or agent of a body corporate (other than a company) who is applying for a licence to operate a pharmacy on behalf of that body corporate (for example, an application made on behalf of a partnership or friendly society): you must make yourself familiar with the provisions of the Medicines Act 1981 and the Medicines Regulations 1984, in particular those provisions relating to licensing and operating pharmacies: the following must accompany this application: the prescribed fee: a completed statutory declaration: it is an offence to make a false statutory declaration: the licensing authority may require you to supply additional information at a later date ( see section 55B of the Medicines Act 1981). If you do not supply that information within 30 days of the request, this application will lapse. Please complete the following: Application ( and body corporate) I, [ full name ], of [ address ], being a resident of New Zealand, apply for a licence to operate a pharmacy on --  *my own behalf. *on behalf of the body corporate called [ name of body corporate ], which --  (a) is not a company, but is a [ specify the type of body corporate ]; and (b) was incorporated in New Zealand on [ date ]; and (c) has the following board members ( or trustees) ( or partners): [ full names of board members (or trustees ) (or partners )]. *Delete if inapplicable. My address ( or The address of the body corporate) is [ address ]. *I was born on [ date ]. or *I hold the office of [ specify office held ] within the above-named body corporate. The following persons are nominated to be responsible persons under the Medicines Act 1981 : [ full names, dates of birth, and positions held ]. *Delete if inapplicable. Street address and description of pharmacy The street address of the pharmacy to which this application relates is [ street address ]. The pharmacy will comprise the following part or parts of that street address: [ specify the part or parts of the street address that are to be a pharmacy or attach a line drawing showing the part or parts ]. Interests held in pharmacy Note : Before filling out this part of the form please read section 5A of the Medicines Act 1981, which sets out the meaning of holding an interest in a pharmacy . The following person(s) or company ( or companies) hold an interest in the pharmacy (as defined in section 5A of the Medicines Act 1981) to which this application relates: [ name(s) of person(s) or company (or companies), their address(es), and the particulars of the interest held (or " none " if applicable) ]. The following person(s) who hold an interest in the pharmacy to which this applicaton relates is a ( or are) practioner(s) ( or registered midwife (midwives)) ( or designated prescriber(s)): [ name of the interest holder(s) and his or her relevant position (or " none " if applicable) ]. Eligibility to hold licence *I am ( or [ Name of person in body corporate who has the majority interest ] is) a pharmacist for the purposes of this application because I am ( or he or she is) a health practitioner who is, or is deemed to be, registered with the Pharmacy Council established by the Health Practitioners Competence Assurance Act 2003 as a practitioner of the profession of pharmacy. or *I am ( or The body corporate is) a pharmacist because [ specify part of the definition of pharmacist in section 55E(3) of the Medicines Act 1981 ] applies. or *The pharmacy I am ( or The body corporate is) applying to operate is in a hospital owned or operated by me ( or the body corporate). [ Specify details .] or *I am ( or The body corporate is) eligible to operate a pharmacy because [ specify other ground in section 55E(1) of the Medicines Act 1981 that makes person or body corporate eligible to hold a licence ]. *Delete if inapplicable. Practices and procedure for pharmacists working in pharmacy The following practices and procedures will be in place to ensure that any pharmacist* who is employed or engaged in duties in the pharmacy to which this application relates is not requested or required to act in a way that is inconsistent with the applicable professional or ethical standards of the pharmacy practice: [ specify practices and procedures ]. Other pharmacies I operate ( or have a majority interest in) ( or The body corporate operates) the following pharmacy ( or pharmacies): [ name(s) and address(es) of the pharmacy (or pharmacies) (or " none " if applicable) .] [ Specify number, or " none " if applicable ] of those pharmacies are ( or is) currently for sale. *Mortgagee in possession I am ( or The body corporate is) the mortgagee in possession+ of the pharmacy to which this application relates. *Delete if inapplicable. +For the purposes of this application a mortgagee in possession has the same meaning as in section 4 of the Property Law Act 2007. Signature of applicant: Declaration I [ full name of applicant ], of [ place ], [ occupation ], solemnly and sincerely declare that the statements made in the above application are true and correct. Form 2 Licence to manufacture medicines The *licensee or every responsible person named above is hereby authorised pursuant to section 51 of the Medicines Act 1981 to manufacture, pack, label, and sell by wholesale the following medicines or classes of medicines: *Delete whichever does not apply. The authority granted by this licence is subject to the following conditions: (1) The manufacture, packing, labelling, or sale of the medicines shall be carried out in accordance with the Medicines Act 1981 and the Medicines Regulations 1984. (2) [ Further conditions imposed by the licensing authority ]: This licence shall expire on [ date ]. [ Signature ] (Licensing authority) Schedule 2 form 2: amended, on 18 September 2004, by regulation 9(2)(a) of the Medicines Amendment Regulations 2004 (SR 2004/300). Schedule 2 form 2: amended, on 18 September 2004, by regulation 9(2)(b) of the Medicines Amendment Regulations 2004 (SR 2004/300). Form 5 Licence to sell medicines by retail The *licensee or every responsible person named above is hereby authorised pursuant to section 51 of the Medicines Act 1981 to sell by retail, and supply in circumstances corresponding to retail sale, the following medicines: *Delete whichever does not apply. The authority granted by this licence is subject to the following conditions: (1) The sale of the above medicines shall not take place other than at the business premises set out above. (2) All sales shall be made in accordance with the Medicines Act 1981 and the Medicines Regulations 1984. (3) [ Further conditions imposed by the licensing authority ]: This licence shall expire on [ date ]. [ Signature ] (Licensing authority) Schedule 2 form 5: amended, on 18 September 2004, by regulation 9(3)(a) of the Medicines Amendment Regulations 2004 (SR 2004/300). Schedule 2 form 5: amended, on 18 September 2004, by regulation 9(3)(b) of the Medicines Amendment Regulations 2004 (SR 2004/300). Form 6 Licence to pack medicines The *licensee or every responsible person named above is hereby authorised pursuant to section 51 of the Medicines Act 1981 to pack or label for the purpose of sale, and sell by wholesale the following medicines: *Delete whichever does not apply. The authority granted by this licence is subject to the following conditions: (1) The packing, labelling, or sale of the medicines shall be carried out in accordance with the Medicines Act 1981 and the Medicines Regulations 1984. (2) [ Further conditions imposed by the licensing authority ]: This licence shall expire on [ date ]. [ Signature ] (Licensing authority) Schedule 2 form 6: amended, on 18 September 2004, by regulation 9(3)(a) of the Medicines Amendment Regulations 2004 (SR 2004/300). Schedule 2 form 6: amended, on 18 September 2004, by regulation 9(3)(b) of the Medicines Amendment Regulations 2004 (SR 2004/300). Form 7 Licence to operate pharmacy This licence to operate a pharmacy is granted to [ full name of person or body corporate ] of [ address ] and authorises --  the establishment of a pharmacy at [ location ] ( or in the following part or parts of [ location ]: [ specify relevant part or parts ]); and the carrying on of pharmacy practice in that pharmacy. *Names of responsible persons for body corporate: *Delete if inapplicable. The pharmacy must be operated in accordance with the duties and obligations in the Medicines Act 1981 . This licence is subject to the following conditions: (a) the holder of this licence must not request or require any pharmacist who is employed or engaged in duties at the above-named pharmacy to act in a way that is inconsistent with the applicable professional or ethical standards of pharmacy practice: (b) [ specify any other conditions ]. This licence expires on [ date ]. [ Signature ] (Licensing authority) Schedule 2 form 7: added, on 18 September 2004, by regulation 11 of the Medicines Amendment Regulations 2004 (SR 2004/300). I, [ name ], an analyst under the Medicines Act 1981 , certify that on [ date ] there was submitted to me by [ name and address of the officer from whom the sample was received ] an officer within the meaning of that Act, a sample of [ name or description of sample ] for analysis in a [ nature of the package in which the sample was enclosed, and how it was labelled, marked, and sealed ] and that the same has been analysed and that the result of the analysis is as follows [ analysis and observations ]: Contents 4 Changes made under section 17C of the Acts and Regulations Publication Act 1989 5 List of amendments incorporated in this reprint (most recent first) Notes 1 General This is a reprint of the Medicines Regulations 1984. The reprint incorporates all the amendments to the regulations as at 1 December 2011, as specified in the list of amendments at the end of these notes. Relevant provisions of any amending enactments that contain transitional, savings, or application provisions that cannot be compiled in the reprint are also included, after the principal enactment, in chronological order. For more information, see http://www.pco.parliament.govt.nz/reprin\\... . 2 Status of reprints Under section 16D of the Acts and Regulations Publication Act 1989, reprints are presumed to correctly state, as at the date of the reprint, the law enacted by the principal enactment and by the amendments to that enactment. This presumption applies even though editorial changes authorised by section 17C of the Acts and Regulations Publication Act 1989 have been made in the reprint. This presumption may be rebutted by producing the official volumes of statutes or statutory regulations in which the principal enactment and its amendments are contained. 3 How reprints are prepared A number of editorial conventions are followed in the preparation of reprints. For example, the enacting words are not included in Acts, and provisions that are repealed or revoked are omitted. For a detailed list of the editorial conventions, see http://www.pco.parliament.govt.nz/editor\\... or Part 8 of the Tables of New Zealand Acts and Ordinances and Statutory Regulations and Deemed Regulations in Force . 4 Changes made under section 17C of the Acts and Regulations Publication Act 1989 Section 17C of the Acts and Regulations Publication Act 1989 authorises the making of editorial changes in a reprint as set out in sections 17D and 17E of that Act so that, to the extent permitted, the format and style of the reprinted enactment is consistent with current legislative drafting practice. Changes that would alter the effect of the legislation are not permitted. A new format of legislation was introduced on 1 January 2000. Changes to legislative drafting style have also been made since 1997, and are ongoing. To the extent permitted by section 17C of the Acts and Regulations Publication Act 1989, all legislation reprinted after 1 January 2000 is in the new format for legislation and reflects current drafting practice at the time of the reprint. In outline, the editorial changes made in reprints under the authority of section 17C of the Acts and Regulations Publication Act 1989 are set out below, and they have been applied, where relevant, in the preparation of this reprint:  omission of unnecessary referential words (such as " of this section " and " of this Act " )  typeface and type size (Times Roman, generally in 11.5 point)  layout of provisions, including:  indentation  position of section headings (eg, the number and heading now appear above the section)  format of definitions (eg, the defined term now appears in bold type, without quotation marks)  format of dates (eg, a date formerly expressed as " the 1st day of January 1999 " is now expressed as " 1 January 1999 " )  position of the date of assent (it now appears on the front page of each Act)  punctuation (eg, colons are not used after definitions)  Parts numbered with roman numerals are replaced with arabic numerals, and all cross-references are changed accordingly  case and appearance of letters and words, including:  format of headings (eg, headings where each word formerly appeared with an initial capital letter followed by small capital letters are amended so that the heading appears in bold, with only the first word (and any proper nouns) appearing with an initial capital letter)  small capital letters in section and subsection references are now capital letters  schedules are renumbered (eg, Schedule 1 replaces First Schedule), and all cross-references are changed accordingly  running heads (the information that appears at the top of each page)  format of two-column schedules of consequential amendments, and schedules of repeals (eg, they are rearranged into alphabetical order, rather than chronological).